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ABSTRACT 
 
Srinivas Ramachandran: Recognition of platinum-dna adducts by hmg-box proteins 
(Under the direction of Nikolay V. Dokholyan) 
 
Cisplatin (CP) and oxaliplatin (OX) are platinum (Pt) based drugs that are widely 
used in chemotherapy.  The mode of action of Pt drugs is through the formation of Pt 
adducts on intrastrand guanines (5’GG) in genomic DNA. A class of proteins that bind 
specifically to Pt adducts contain the HMG-domain, which is found in both abundant 
housekeeping proteins like HMGB1 and also in low abundance transcription factors. The 
differential affinity of HMG-domain proteins to CP- and OX-DNA may play a role in the 
differential efficacies of CP- and OX-DNA. In this study, we aim to understand the 
molecular basis of the differential affinity of HMGB1a to CP- and OX-DNA, given that the 
only differences between these two species is their carrier ligand, which is not even 
involved in the Protein-DNA interface. We hypothesized that the differences in 
conformational dynamics rather than the major conformation of Pt-DNA determines the 
differential binding affinity to HMGB1a. To test this hypothesis, we performed molecular 
dynamics simulations of both free Pt-DNA and HMGB1a-Pt-DNA complexes. Our 
simulations of free Pt-DNA revealed that the conformational dynamics of CP- and OX-
GG adducts are distinct and depend on the sequence context of the adduct. We found 
that the minor conformations sampled exclusively by the CP-GG adduct exhibit structural 
properties that favor binding by HMGB1a, while these conformations are not sampled by 
OX-GG adducts. Comparing the conformations of Pt-DNA in three sequence contexts 
revealed the sequence and carrier ligand dependent distortions induced by the Pt-GG 
adduct. Finally, simulations of HMGB1a-Pt-DNA revealed that the lack of flexibility of 
iv 
OX-DNA in the TGGA sequence context seen in free Pt-DNA translated to a much 
weaker binding interface compared to CP-DNA, thus explaining the experimentally 
observed low binding affinity of OX-DNA compared to CP-DNA. Based on these results, 
we postulate that the carrier ligand affects the DNA conformations explored by Pt-GG 
adduct, which influences the binding affinities of HMG-domain proteins for Pt-GG 
adducts, and that these conformations are further influenced by the DNA sequence 
context of the Pt-GG adduct. 
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CHAPTER 1. Introduction 
Platinum (Pt) based drugs are widely used chemotherapy agents. Even 40 years 
after the serendipitous discovery of the first Pt-drug, Pt-based chemotherapeutic 
regimens are still the treatment of choice for many solid tumors, and are increasingly 
being used in combination with newly developed targeted therapies (Wang and Lippard, 
2005). Since the discovery of the first Pt drug, more than 3000 analogs with a Pt core 
have been developed (Weiss and Christian, 1993), but to date, only cisplatin (cis-
Diamminedichloroplatinum(II), CP), carboplatin (cis-diammine-1,1-cyclobutane 
dicarboxylate) and oxaliplatin ( (trans-R,R)1,2-Diaminocyclohexaneoxalatoplatinum(II) 
have been approved for clinical use in the US (Figure 1.1). 
Unfortunately, treatment with CP is accompanied by serious side effects that 
include nephrotoxicity, neurotoxicity, ototoxicity, nausea and vomiting which are dose-
limiting. Even though carboplatin has the same tumor range as CP, and in many cases 
is less effective, it is mainly used in treatment due to the reduced severity of the side 
effects in carboplatin treatment as compared to CP treatment. OX, which is approved for 
only colon cancer in the US, has side effects that include neuropathy, nausea, vomiting 
and diarrhea. Another major disadvantage of CP and carboplatin in cancer therapy is the 
innate and acquired resistance to CP and carboplatin exhibited by many tumors.  
Pt drugs are widely used despite their serious side effects because of their 
effectiveness in inhibiting proliferation in a broad spectrum of cell types. CP and 
carboplatin are used in the treatment testicular, ovarian, head, neck and non-small cell 
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lung cancer. CP is especially effective in treating testicular cancer, with cure rates of 
90% (Bosl, et al., 2008). OX is used in the treatment of colorectal and other cancers, 
where CP is not effective. Thus, the Pt drugs currently in use present a double edged 
sword: they are some of the most potent chemotherapeutic agents in use, but their 
severe side effects and acquired resistance severely limit their effectiveness. These 
disadvantages of currently approved Pt drugs have prompted exploration of several 
analogs. However, understanding the biological mechanisms that are involved in 
Pt cytotoxicity and Pt resistance is essential to develop better chemotherapeutic 
agents. 
 
Figure 1.1. Platinum drugs and their GG intrastrand adducts on DNA 
1.1. Mechanism of Cytotoxicity and Resistance 
Pt drugs reduce proliferation of tumor cells by directly bringing about cancer cell 
death. In this regard, Pt drugs bring about death of any dividing cells by forming Pt-DNA 
adducts. Thus, the various processes that affect Pt drug effectiveness would include 
cellular uptake and efflux of the drug, transport of the drug to the nucleus, adduct 
formation on genomic DNA, recognition of Pt-DNA adducts by a host of DNA-binding 
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proteins including DNA damage response proteins and the subsequent activation of 
various cellular pathways that lead to apoptosis, necrosis, repair or mutagenesis (Jung 
and Lippard, 2007) (Figure 1.2). Pt drug sensitivity would be increased by effective 
uptake, minimal efflux, effective transport to nucleus, high density of adduct formation, 
and activation of downstream pathways that lead to apoptosis. It is important to note that 
not only increasing the rate of apoptosis, but also reducing efflux and repair rates would 
increase Pt drug effectiveness. 
 
Figure 1.2. Transport and cellular fate of Pt drugs. 
The most significant aspects of cisplatin (CP) and oxaliplatin (OX) cellular toxicities are illustrated. 
The primary mode of cellular uptake of Pt drugs has been thought to be by 
passive diffusion since the drug uptake by cells is not saturable (Binks and Dobrota, 
1990; Gale, et al., 1973; Hromas, et al., 1987) and uptake of a Pt drug is not inhibited by 
its analogs (Gately and Howell, 1993). Additionally, proteins involved in copper 
homeostasis (including copper transporters and chaperones) have been implicated in 
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drug uptake and efflux (Safaei and Howell, 2005). Organic Cation Transporters 
(especially OCT2) are thought to be responsible for nephrotoxicity of CP due to their 
selective expression in kidney, where they are the main mediators of Pt drug uptake 
(Ciarimboli, et al., 2005; Yonezawa, et al., 2006). 
Upon cellular entry, the leaving groups (two chloride ligands in CP and oxalate 
ligand in OX) are replaced by two water ions, conferring a net positive charge on the 
drugs (Pinto and Lippard, 1985), which would be effective in reducing the rate of efflux 
by passive diffusion through the membrane. Aquated CP and OX can form adducts with 
protein, RNA, and thiol-containing molecules like glutathione (Jung and Lippard, 2007). 
However, the largest amount of Pt adducts are formed on DNA, which has also been 
shown to be the primary cause of the cytotoxic effects of Pt drugs (Jung and Lippard, 
2007). Pt adducts on DNA are formed through the reaction of Pt with N7 atoms of 
guanine or adenine (Bancroft, et al., 1990). Consequently, monofunctional adducts on 
adenine and guanine, and bifunctional interstrand, intrastrand adducts with either 
adenine or guanine or both are possible. However, calculations have shown that only 
AG, GG, GNG intrastrand adducts and interstrand adducts are probable (Baik, et al., 
2003). In cellular DNA, both CP and OX form the same type of adducts at the same 
sites: 60-65% intrastrand GG, 25-30% intrastrand AG, 5-10% intrastrand GNG and 1-3% 
interstrand GG diadducts (Eastman, 1987). 
The recognition of Pt-DNA adducts by various cellular proteins trigger 
downstream pathways that lead to either apoptosis or necrosis or the repair of lesions 
(Jung and Lippard, 2007). Repair of lesions is the most effective form of Pt drug 
resistance as it returns the DNA to pre-drug state. The main modes of repair of Pt-DNA 
adducts involve the Nucleotide excision repair (NER) pathway, recombination repair 
pathway and mismatch repair  (MMR) pathway (Chaney, et al., 2005). NER is the most 
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effective form of repair of Pt-DNA lesions in cells, with cell lines deficient in NER 
pathway showing increased sensitivity to Pt drugs (Furuta, et al., 2002). Furthermore, 
CP-resistant cell lines have been shown to have increased levels of NER pathway 
transcripts (Weaver, et al., 2005). NER is efficient in repairing 1,3-GNG and 1,2-GG 
intrastrand and interstrand Pt-DNA adducts (Zamble, et al., 1996). Effective MMR is 
thought to be very important in CP sensitivity as opposed to NER, which may contribute 
to CP resistance (Chaney, et al., 2005). MMR pathway proteins actively seek to repair 
mismatches on newly synthesized DNA across Pt adducts, which if repeatedly 
unsuccessful would trigger ATR checkpoint (Jiricny, 2006). MMR also mediates DNA 
damage induced apoptosis (Bellacosa, 2001). MMR’s role in CP sensitivity is highlighted 
by the fact that many CP-resistant cell lines feature defects in the MMR pathway 
(Vaisman, et al., 1998). 
Pt-DNA adducts also block DNA- and RNA-polymerases during the process of 
replication and transcription respectively (Chaney, et al., 2005). Blockage of DNA-
polymerases ,  and  results in the recruitment of error-prone bypass polymerases that 
attempt to replicate past the Pt adducts (Bassett, et al., 2003; Havener, et al., 2003; 
Vaisman, et al., 2000). Failure to bypass Pt adducts leads to cell cycle arrest (Siddik, 
2003), while error-prone bypass results in mutations at the adduct site in daughter cells 
(Chaney, et al., 2005). These mutations are thought to lead to the development of 
secondary tumors or Pt drug resistance (Chaney, et al., 2005). Block of RNA-
polymerase by Pt-DNA adducts on the other hand results in multiple outcomes. RNA 
pol II blocked by CP-DNA adducts has been shown to be mono- and poly-ubiquitinated, 
which may or may not lead to its degradation (Jung and Lippard, 2007). Blocked RNA 
pol II also triggers NER (through transcription coupled repair) and has been shown to 
mediate pathways that lead to programmed cell death (Svejstrup, 2003). 
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1.2. Interaction of Pt-DNA adducts with proteins 
One of the major determinants of the eventual fate of cells exposed to Pt drugs is 
the recognition of Pt-DNA adducts by proteins that specifically interact with Pt-DNA or 
encounter Pt-DNA during the course of their function (polymerases for example). Some 
of the proteins shown to bind specifically to Pt-DNA adducts include XPC, XPA, RPA 
(part of NER pathway), hMSH2, hMutSalpha (part of MMR pathway), Ku80, P53, PARP-
1, YB-1 (DNA damage response proteins) and TBP (transcription factor) (Chaney, et al., 
2005). However, the highest specificity for binding Pt-DNA has been exhibited by HMG-
domain proteins. Several HMG domain proteins such as HMG1 (Pil and Lippard, 1992), 
HMG2 (Lawrence, et al., 1993), Ixr1 (Brown, et al., 1993; McA'Nulty and Lippard, 1996), 
tsHMG (Ohndorf, et al., 1997), SRY (Chow, et al., 1994), SSRP1 (Yarnell, et al., 2001), 
LEF-1 (Chow, et al., 1994; Chvalova, et al., 2008) and hUBF (Treiber, et al., 1994; Zhai, 
et al., 1998) bind with high affinity to Pt adducts. Proteins with HMG-domain that bind to 
Pt-GG adducts fall into two classes: structure-specific, abundant, chromatin architectural 
proteins like HMGB1 and sequence-specific, cell-type specific transcription factors like 
LEF-1 and SRY. The binding of structure-specific HMG-domain proteins to Pt-DNA 
adducts has been shown to inhibit nucleotide excision repair (Huang, et al., 1994; 
McAnulty and Lippard, 1996), which may increase the longevity of Pt-DNA adducts. Pt-
DNA adducts have also been postulated to sequester some HMG-domain containing 
transcription factors that are essential for maintaining the uncontrolled cell growth 
characteristic of tumor cells (Treiber, et al., 1994; Zhai, et al., 1998). Thus, the binding of 
HMG-domain proteins to Pt-DNA could significantly sensitize cells to CP and OX. 
A crystal structure of HMGB1a in complex with CP-GG DNA in the TGGA 
sequence context (Ohndorf, et al., 1999) has been reported (Figure 1.3). That structure, 
coupled with site-directed mutagenesis, has provided considerable insight into the 
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mechanism of HMGB1a binding to Pt-DNA adducts, which can be extrapolated to 
understand binding of other HMG-domain proteins to Pt-DNA adducts. There are a 
number of hydrophobic and hydrogen bond interactions between HMGB1a and the 
minor groove of DNA on the 3’ side of the CP-GG adduct. Among these interactions, the 
most significant appears to be the intercalation of Phe37 between the two Gs of the Pt-
GG adduct, which allows a - stacking interaction between Phe37 and the 3’ G (Figure 
1.3B). Mutation of Phe37 to Ala resulted in more than 667-fold decrease in binding 
affinity (He, et al., 2000). Thus, Phe37 in HMGB1a specifically recognizes the distortion 
caused by formation of the Pt-GG adduct. Several other structures of HMG-domain 
proteins bound to undamaged DNA reveal similar intercalation, but involving different 
residues (methionine, in LEF-1 (Love, et al., 1995) and isoleucine in SRY (Werner, et al., 
1995)for example). 
 
Figure 1.3 The Pt-DNA-HMGB1a Complex 
A) The crystal structure of HMGB1a bound to CP-DNA (PDB ID 1CKT) B) A zoomed in view 
showing the important interactions C) The Domain structure of HMGB1  
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The crystal structure of HMGB1a bound to Pt-DNA in the TGGA sequence 
context (Ohndorf, et al., 1999) also shows a hydrogen bond between Ser41 and the N3 
atom of Adenine 3’ of the Pt-GG adduct (Figure 1.3B). A Ser41Ala mutation resulted 
only in a 3.9-fold decrease in binding affinity, a much weaker effect than the Phe37Ala 
mutation (He, et al., 2000). This interaction would depend on the conformation of the 
base-pair on the 3’ side of the adduct, which may be influenced by the sequence context 
of the adduct. The contributions of other interactions between HMGB1a and the minor 
groove of Pt-DNA adducts to the binding affinity of the protein-DNA complex have not 
been characterized, but are likely to be less than or equal to the Ser41-3’A-N3 
interaction. 
1.3. Proposed mechanisms of cellular discrimination between CP and 
OX 
One of the phenomena that add to the complexity of cellular toxicity due to 
Pt drugs is the difference in tumor range of CP and OX. Even though CP and OX form 
similar adducts at similar sites on DNA, cells and tumors that are resistant to CP are 
generally not cross resistant to OX (Chaney and Vaisman, 1999; Rixe, et al., 1996). The 
lack of cross-resistance of cells to CP and OX is thought to be in part due to the effects 
downstream of formation of CP- and OX-DNA adducts (Chaney, et al., 2005). Since the 
only difference between CP and OX is their carrier ligand, the differences in 
cytotoxicity indicate the importance of carrier ligand in the overall effect of a Pt 
drug. Thus, understanding the molecular basis of differences in cytotoxicity 
between CP and OX will provide information for better design of Pt drug analogs. 
Strikingly, many of the elements of Pt-DNA response discussed in 1.2 do not 
influence the difference in sensitivity of tumors to CP and OX. NER and recombination 
repair have been shown to not distinguish between CP- and OX-DNA adducts (Reardon, 
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et al., 1999; Wu, et al., 2004). In contrast to NER status, MMR proficiency selectively 
sensitizes cells to CP, but even mismatch repair proficient colon cancer cells are more 
sensitive to OX than to CP (Vaisman, et al., 1998). Moreover, the effect of MMR on the 
cytotoxicity of CP-DNA adducts is 2-fold or less (Aebi, et al., 1996; Drummond, et al., 
1996; Fink, et al., 1996), while differences in the cytotoxicity of CP- and OX-DNA 
adducts are often 5-10-fold (Page, et al., 1990; Schmidt and Chaney, 1993). Replicative 
DNA polymerases and most translesion polymerases are blocked by OX-DNA and CP-
DNA adducts with equal efficiency (Chaney and Vaisman, 1999; Havener, et al., 2003). 
Pol  is somewhat better at bypassing OX-DNA adducts than CP-DNA adducts 
(Vaisman, et al., 2000), but the outcome of this difference is manifested as differences in 
mutagenicity rather than cell survival (Bassett, et al., 2004). Taken together these 
observations indicate that important cellular activities other than DNA repair proficiency 
influence cellular sensitivity to different platinum drugs. 
In contrast to the lack of discrimination between CP- and OX- by different repair 
recognition proteins, HMG-domain proteins like HMGB1, LEF-1, TBP and hUBF are 
known to bind CP- and OX adducts with different affinities (Chvalova, et al., 2008; 
Malina, et al., 2007; Wei, et al., 2001). Consequently, the differential binding affinities of 
HMG domain proteins to CP- and OX-DNA adducts have been proposed to contribute to 
the distinctive cellular effects of CP- and OX-DNA adducts. For example, HMGB1 has 
also been shown to inhibit translesion synthesis past CP-adducts to a greater extent 
compared to OX-adducts (Vaisman, et al., 1999) and will similarly be expected to shield 
CP-adducts from NER better than OX-adducts. Furthermore, HMGB1 expression is 
elevated in many cancer types, including colorectal cancers (Volp, et al., 2006), which 
frequently display resistance to CP but not OX (Raymond, et al., 1998; Rixe, et al., 
1996). Hence, understanding the basis of the differential binding of HMG domain 
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proteins to CP- and OX-DNA could lead to a better understanding of the differential 
efficacies of CP and OX. 
The binding of HMGB1 to Pt-DNA adducts has been characterized in great detail. 
HMGB1 contains two HMG domains: domain A (HMGB1a) and domain B (HMGB1b) 
(Figure 1.3C). HMGB1a binds more strongly than HMGB1b to most Pt-GG DNA adducts 
(Wei, et al., 2001). Full length HMGB1 binds with lower affinity compared to HMGB1a 
mainly due to its highly acidic C-terminal tail (Figure 1.3C), which when removed results 
in the tandem HMG domains having same affinity as HMGB1a (Jung and Lippard, 
2003). However, HMGB1a binds to Pt-GG adducts with the same specificity as full 
length HMGB1 (Jung and Lippard, 2003).  Further, footprinting studies combined with 
site-directed mutagenesis have shown that only domain A of full length HMGB1 binds to 
DNA containing the Pt-GG DNA adduct (He, et al., 2000; Jung and Lippard, 2003). Thus, 
most of the structural and mechanistic studies have been performed with HMGB1a 
alone. The differential binding affinity of HMGB1a towards CP- and OX-DNA is also 
dependent on the identity of bases flanking the central intrastrand GG (Malina, et al., 
2007; Wei, et al., 2001). The binding affinity of HMGB1a for CP-DNA adducts has been 
shown to be ~53 times greater than that for OX-DNA adducts in the TGGA sequence 
context (Wei, et al., 2001) while in the AGGC (Wei, et al., 2001) and the CGGA (Malina, 
et al., 2007) sequence contexts, the binding affinity for CP-DNA is only 3 times greater 
than that of OX-DNA adducts. In the TGGT sequence contest, the binding affinity of 
HMGB1a for CP-GG and OX-GG adducts is almost the same (Malina, et al., 2007). Most 
of the sequence-dependent variations in differential binding affinity of HMGB1a towards 
CP- and OX-DNA adducts is due to sequence dependent effects for binding to OX-DNA 
adducts since the binding affinity of HMGB1a for CP-GG adducts is roughly comparable 
in all three sequence contexts (Malina, et al., 2007; Wei, et al., 2001). This sequence 
11 
dependent effect has also been shown for HMGB1b and TBP, but the trends are slightly 
different (Wei, et al., 2001). 
1.4. Distortion of DNA structure by Pt-adduct formation 
Since the differential cellular effects of CP and OX seem to stem from differential 
binding of proteins to CP- and OX-DNA adducts, we could expect significant differences 
in the structures of CP- and OX-DNA adducts, leading to differential recognition. To 
examine the effect of Pt-adducts on DNA structure, oligomers made up of 8-12 base-
pairs, containing single Pt-adducts have been characterized in great detail by Xray 
crystallography and NMR spectroscopy (Gelasco and Lippard, 1998; Herman, et al., 
1990; Marzilli, et al., 2001; Spingler, et al., 2001; Takahara, et al., 1996; Wu, et al., 2007; 
Wu, et al., 2004; Yang, et al., 1995). Even though various types of adducts like 
monofunctional, interstrand and GNG intrastrand adducts have been characterized, the 
structural characteristics of the most abundant adducts; the 1,2 GG intrastrand adducts 
are of importance, especially because HMG-domain proteins selectively bind these 
adducts. Pt-GG adducts are formed on the major groove of DNA, where the N7 atoms of 
the guanines are exposed. The geometry of the Pt ligands induces a large roll in the 
platinated GG base-pair step. The increased roll directly leads to the pronounced 
bending of DNA towards the major groove. The helix is also locally unwinded at the site 
of the adduct and the minor groove is shallow and wide.  
Comparing the structures of CP- and OX-DNA adducts in the same sequence 
context (TGGT) by X-ray crystallography revealed almost identical structures. In the 
AGGC sequence context, where binding of HMGB1a to CP- and OX-DNA differs by 3 
fold, only minor differences were detected in structural characterization by NMR. In the 
TGGA sequence context, where the differences in binding energy is almost 53-fold, MD 
simulations indicate minimal differences in the overall conformations of CP- and OX-
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DNA. Thus, structural studies indicate no major structural differences in average 
conformations between CP- and OX-DNA in three different sequence contexts. 
Furthermore, the carrier ligand cannot influence binding affinity by direct interactions with 
the protein since the HMG-domain proteins and TBP bind to the major groove of DNA, 
while the adduct is formed on the major groove. 
1.5. Motivation 
The structural data for CP- and OX-DNA adducts suggest that the average 
conformation of CP- and OX-DNA adducts are similar. Further, since the HMG-domain 
proteins and TBP bind DNA through the minor groove, the carrier ligand could influence 
binding only indirectly. Even though the average structures of CP- and OX-DNA are 
similar, the conformational dynamics of DNA may lead to some minor conformations of 
CP- and OX-DNA to be distinct from each other. These minor conformations may 
facilitate increased binding to HMG-domain proteins, thus influencing the differential 
binding affinities observed. Thus, we have hypothesized that differences in the 
conformational dynamics of CP and OX adducts may give rise to the differences in their 
activity. 
In this study, we use molecular dynamics simulations, which can probe short 
time-scale conformational dynamics, to examine the effect of carrier ligand on the 
conformational space of free Pt-DNA. We then perform simulations of HMGB1a-Pt-DNA 
complex to explore the differences in the binding interfaces of HMGB1a with CP- and 
OX-DNA that lead to their differential binding affinities. These simulations provide the 
molecular basis of differences in binding of HMGB1a to CP- and OX-DNA and also 
illustrate the effect of carrier ligand on the conformational dynamics and flexibility of Pt-
DNA.
Chapter 2. Materials and Methods 
2.1. DNA and protein constructs used in the simulations 
Pt-DNA Simulations. We performed simulations on a 12-mer DNA sequence 
(shown in Scheme 1), which was either undamaged or covalently bound to CP or OX at 
the N7 of G6 and G7. We used the solution structure of OX-TGGT adduct determined by 
NMR spectroscopy as the starting structure for the OX-TGGT simulations. In the same 
structure, the adduct was modified to cisplatin for the CP-TGGT simulations. The initial 
structures for the CP- and OX-TGGA simulations were obtained by modifying the NMR 
structure of OX-DNA in the TGGT sequence context. We chose this structure because of 
the NMR solution structures of Pt-DNA adducts that we have obtained it was closest in 
sequence to the TGGA sequence context. Using INSIGHT II (Accelrys Inc., CA), the T8-
A17 base pair was replaced by the A8-T17 base pair in the TGGT NMR structure to 
obtain the initial structure of OX-DNA in TGGA sequence context. Further, OX was 
modified to CP to obtain CP-DNA structure in the TGGA sequence context. INSIGHT II 
was used to generate canonical B-DNA structure, which was used as the starting 
structure for simulations of the undamaged DNA. Data for the AGGC sequence context 
were obtained from simulations that were performed as part of an earlier work (Sharma, 
et al., 2007). 
HMGB1a-Pt-DNA Simulations. For the simulations of HMGB1a-Pt-DNA 
complex, we used the crystal structure of rat HMGB1a bound to CP-DNA in the TGGA 
sequence context as the starting structure for the CP-TGGA simulations (PDB ID 1CKT 
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(Ohndorf, et al., 1999)). This structure was modified appropriately using Insight II to 
generate starting structures for OX-TGGA, CP-AGGC and OX-AGGC simulations. 
 
2.2. Force Field. 
The force field parameters used for DNA and protein were from the Duan et al. 
force field (Cornell, et al., 1995; Duan, et al., 2003) with the ff03 parameter set. The 
partial charges for the Pt-GG adducts were derived by Sharma et al. (Sharma, et al., 
2007). In order to determine the atomic partial charges of CP-GG and OX-GG adducts, 
the 9-methyl-guanine derivatives cis- [Pt(NH3)2(9-Me-Guo)2]2+ (CP-meG2) and 
[Pt(trans-RR-1,2-diaminocyclohexane)(9-Me-Guo)2]2+ (OX-meG2) were used. These 
derivatives were built from our NMR solution structures using Insight II. The atomic 
partial charges were determined using the Mulliken method implemented within 
Gaussian03 based on the NMR structure modified to the 9-methyl-guanine derivative. 
The density functional method B3LYP implemented within Gaussian03 was utilized; the 
LanL2DZ basis set was used for the platinum atom and 6-31Gd basis set was used for 
the rest of the atoms. Besides the atomic partial charges, other force field parameters of 
the Pt-GG adducts were referenced from AMBER parm99 force field parameters or from 
previous work by Yao et al (Yao, et al., 1994). and Scheeff et al (Scheeff, et al., 1999).  
15 
2.3. MD Simulations 
Pt-DNA Simulations. We performed five sets of simulations of CP-, OX- and 
undamaged DNA in the TGGT and TGGA sequence contexts. Similar starting structures 
but randomized initial velocities were used in each of the five sets of simulations. The 
starting structures described above were first modified by removal of hydrogen atoms in 
Insight II. The structures were then prepared by LEaP module of AMBER v8.0 as 
follows: First hydrogen atoms were added back according to the nucleotide templates in 
AMBER force field library. Secondly the structures were neutralized with Na+ ions. 
Thirdly the neutralized system was fully solvated in an octahedral water box using TIP3 
model water molecules. The distance between the wall of the periodic box and the 
closest atom in the solute was set to be 12.5 Å. The Duan et al. force field (Cornell, et 
al., 1995; Duan, et al., 2003) with the ff03 parameter set was used, as well as our self-
defined force field parameters for Pt-GG adducts. 
Simulation Parameters. The non-bonded cutoff was set to be 9.0 Å and the 
non-bonded list was updated every 10 steps. The MD simulations were always carried 
out in NPT condition (constant pressure, using isotropic position scaling, at 1 atm (1 atm 
= 6.9 kPa), pressure relaxation time constant 0.2 ps in relaxation MD and 2 ps in 
production MD; constant temperature, using weak-coupling algorithm, at 300 K, heat 
bath coupling time constant 0.2 ps in relaxation MD and 1 ps in production MD) with a 1 
fs time step. The SHAKE algorithm was applied to all bonds involving hydrogen atoms 
and in turn the regular force evaluation omitted for those bonds. The translational center-
of-mass motion was removed every 1 ps. Every time when the system was heated, zero 
velocity information was inherited from the previous stage and a Maxwell distribution of 
velocities was re-established. In minimization and relaxation, a harmonic potential was 
applied to Pt-DNA adduct or DNA to restrain its motion. The restraint was gradually 
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weakened and became zero at the final stage of relaxation. The following 10 ns 
production MD was carried out unrestrained. 
Simulation Protocol. The whole system underwent 120 ps minimization and 
relaxation before a 10 ns production MD carried out by the SANDER module of AMBER 
v8.0. The details of system minimization and relaxation were as follows. First, the whole 
system, including Pt-DNA adducts or undamaged DNA, water molecules and counter-
ions, was minimized for 2000 steps using the steepest descent method in constant 
volume condition with a harmonic potential of 500 kcal/mol Å2 (1 cal = 4.184 J) applied to 
Pt-DNA or DNA to fix its conformation. Second, the system was heated from 0 K to 300 
K and kept in NVT (constant volume and constant temperature) condition with the 
harmonic restraints unchanged in a 20 ps relaxation MD. Third, the system was further 
relaxed in another short 20 ps MD in NPT condition with the same harmonic constraints. 
Fourth, the system was further minimized for 2000 steps of steepest descent in constant 
volume condition three times, with a weakening harmonic potential of 500, 50 and 5 
kcal/mol Å2 respectively. Fifth, the system was heated from 10 K to 300 K and kept in 
NVT condition with the harmonic restraints of 5 kcal/mol Å2 in a 20 ps relaxation MD. 
Sixthly, four rounds of 20 ps relaxation MD were carried out in NPT condition with a 
further weakening harmonic potential of 5, 1, 0.1 and 0 kcal/mol Å2 respectively. 
Seventhly, the system was heated up from 10 K to 300 K in NVT condition with zero 
restraints in a 20 ps relaxation MD. Finally, the system was heated for the very last time 
from 100 K to 300 K at the beginning of 10 ns production MD. 
HMGB1a-Pt-DNA Simulations. We performed three sets of 50 ns simulations 
for CP-, OX- and undamaged DNA bound to HMGB1a in the TGGA, AGGC and TGGT 
sequence contexts. The starting structures were similar for each of the three simulations, 
but the initial velocities were randomized. The starting structures described above were 
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prepared in a manner identical to that of free Pt-DNA, except that LEaP v.9.0 was used 
and the crystallographic waters were retained while building the system. The MD 
simulation parameters were identical to the free Pt-DNA simulations. 
Simulation Protocol. The whole system underwent 140 ps minimization and 
relaxation before a 50 ns production MD carried out by the PMEMD module of AMBER 
v9.0. First, the whole system, including Pt-DNA adduct, protein, water molecules and 
counter-ions, was minimized for 5000 steps using the steepest descent method in 
constant volume condition. Second, the system was heated from 0 K to 300 K and in 
NVT (constant volume and constant temperature) conditions in a 20 ps relaxation MD. 
Third, the system was further relaxed in 100 ps MD in NPT. Finally, the system was 
heated from 200 K to 300 K in NVT condition for a 20 ps run before beginning the 50 ns 
production MD. 
2.4. Analysis Protocols 
Hydrogen bonds. All the trajectories were analyzed for the presence of 
hydrogen bonds between all possible donors and acceptors based on a distance cut-off 
of 3.5 Å between the donor and acceptor and an angular cut-off of 135º between donor-
H-acceptor. In the free Pt-DNA simulations, in addition to the Watson-Crick interactions, 
hydrogen bonds were formed for a significant amount of time between Pt-amines and 
the surrounding base pairs. All the frames of the trajectory were classified based on the 
type of hydrogen bonds formed between Pt-amines and the adjacent bases. 
Centroid structures. We calculated the average structures for both the 
complete ensembles of CP-, OX- and undamaged DNA and also for the ensembles 
forming different hydrogen bonds. Since average structures are not actual structures 
from simulations and may feature some abnormal bond lengths/angles, we assigned the 
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structure from each ensemble that had the lowest mass-weighted root-mean-square 
deviation (RMSD) to the average structure as the centroid structure of that 
ensemble (Sharma, et al., 2007). 
Comparisons of structures using root mean square deviation (RMSD). We 
used RMSD to compare centroid structures from different ensembles. In these 
comparisons, we used only the atoms from the DNA part of the molecule in calculating 
the RMSD. 
Helical parameters. Helical parameters were calculated for each snapshot of 
the trajectory using the CURVES program, version 5.3 (Lavery and Sklenar, 1996). The 
following CURVES parameters were extracted: global inter base-pair parameters: shift, 
slide, rise, tilt, roll and twist; global base-base parameters: shear, stretch, stagger, 
buckle, propeller and opening. Histograms were then constructed for each of these 
parameters as frequency of occurrence versus discrete units of each DNA helical 
parameter. The discrete units (bin width) were set as 0.2 Å for all the distance 
parameters and 2º for all the angular parameters. Histograms were plotted for 
parameters corresponding to the central 4 base pairs of the DNA oligomer (the adduct is 
formed on central 2 base pairs). These distributions were also clustered on the basis of 
the pattern of hydrogen bond formation between the DNA and the drug.  
To calculate the P-value of the difference between helical parameters 
corresponding to CP-, OX-DNA and undamaged DNA and also between different 
hydrogen bonded species in CP- and OX-DNA, we used the Kolmogorov-Smirnov (KS) 
test (Press, et al., 1992). The lower cut-off threshold of significant differences was 
calculated by dividing each data set into 5 equal subsets and performing KS test 
comparing all possible combinations of the 5 subsets of divided data. The highest –
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log(P) among the subsets of each data set was set as the threshold for that data set. 
When two data sets were compared, the difference between them was significant only if 
–log(P) of the comparison of the data sets was higher than the threshold. The ratio of –
log(P) of the comparison of the data sets to their thresholds was calculated and then this 
ratio for all the parameters are represented as colors in a diagram (heat map). The ratios 
transition from white (lowest ratios) to blue then red (highest ratios) in the heat map. The 
range of KS ratios and their corresponding color are shown as a scale in the bottom of 
the heat maps. 
Bend angle. Overall bend angles of the snapshots from the simulations were 
calculated using the program MADBEND (Strahs and Sclick, 2000). MADBEND uses the 
local tilt and roll parameters from the CURVES (version 5.3) output to calculate the 
overall bend angle. The bend angle was calculated for the central 10 base pairs of the 
oligomer centered at G6-G7 where the Pt-adduct is formed. The normalized histograms 
were plotted for bend angle versus percent occupancy with a bin width of 2º. The bend 
angle values were also clustered on the basis of the type of hydrogen bond formed. 
Analysis of the Protein-DNA Interface. In the HMGB1a-Pt-DNA simulations, 
the protein-DNA interface was primarily characterized by determining Protein-DNA 
interface contacts. We define an interface contact as a heavy atom from protein and a 
heavy atom from DNA within 5 Å of each other. Using this definition, we determine the 
total number of interface contacts in a given snapshot and build histograms of this 
measure across simulations. We also determine the contact map for a given ensemble. 
A contact map is a matrix, where the each row is a nucleotide and each column is a 
protein residue. The elements of the matrix are the total number of contacts between 
each nucleotide (row) and each residue (column). These contact maps are represented 
as colors in a diagram (heat map). The values transition from white (lowest number of 
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contacts) to blue then red (highest number of contacts) in the heat map. The range of 
the number of contacts and their corresponding color are shown as a scale in the bottom 
of the heat maps. Contact maps from two different ensembles are further compared by 
subtracting one from another, generating a difference-contact map, which is also 
represented as a heat map. Another measure used in analyzing the protein-DNA 
interface is the fraction of native contacts. The fraction of native contacts is the ratio of 
the number of native contacts formed in a given structure to the total number of native 
contacts. We obtained the list of native contacts from the HMGB1a-CP-DNA crystal 
structure determined in the TGGA sequence context.  
Chapter 3. Simulations of CP- and OX-DNA in the 
TGGA sequence context 
A number of cellular proteins containing the HMG-domain have differential 
binding affinities to CP- and OX-DNA adducts (Chvalova, et al., 2008; Wei, et al., 2001; 
Zhai, et al., 1998), which might be important in determining the differential downstream 
effects of formation of CP- and OX-DNA adducts. Understanding the molecular basis of 
this differential binding is essential to uncover the effect of carrier ligand in protein 
binding. The lack of major differences between experimental structures of CP- and OX-
DNA suggests that the major conformations of CP- and OX-DNA in a given sequence 
context are similar and are not the major drivers of the differential affinities to proteins. 
Thus, either minor conformations and/or difference in flexibility between CP- and OX-
DNA should drive the differential binding affinities. Hence, we postulated that the 
differences in conformational dynamics of CP- and OX-DNA adducts might be 
responsible for the differential recognition of these adducts by HMG-domain proteins. To 
test this hypothesis, we performed all-atom molecular dynamics simulations on 
undamaged 12-mer DNA and CP- and OX-GG 12-mer DNA adducts in the TGGA 
sequence context in which the discrimination of HMGB1a between CP- and OX-GG 
adducts is 53-fold. The simulations attained equilibrium within the first few nanoseconds, 
with the all-atom mass weighted RMSD of OX- and undamaged DNA remaining less 
than 3 Å and that of CP-DNA remaining less than 4 Å throughout the simulation (Figure 
3.1).  
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Figure 3.1. Average RMSD values for the MD simulations over time.  
The RMSD values for each of the 5 simulations compared to the corresponding starting structure 
for the undamaged DNA, CP-DNA and OX-DNA are shown for the full 10 ns of each simulation. 
RMSD at time t represents the average of RMSD in a 250 ps bin centered at t (running average). 
The five simulation trajectories starting from undamaged DNA, CP-DNA and OX-DNA structures 
with different initial MD velocities are represented in black, red, blue, green and violet. 
3. 1. The overall conformation of CP- and OX-GG adducts are similar  
We first compared the centroid structures of CP- and OX-DNA simulations in the 
TGGA and the AGGC sequence contexts (Figure 3.2). The all-atom RMSD was ~2 Å 
when we compared either CP-TGGA with CP-AGGC or OX-TGGA with OX-AGGC, 
indicating lack of global structural differences in the major conformations sampled by 
CP- and OX-DNA adducts in the two sequence contexts. Even when we compared the 
centroid structures of CP- and OX-DNA in the TGGA sequence context (Figure 3.3C, 
RMSD=1.98 Å), there were no large conformational differences. The same comparisons 
for the central four base pairs of the centroid structures (Figure 3.2, D-F) yielded the 
same conclusion: the centroid structures did not display any major structural differences 
that would warrant high differential binding affinities between CP- and OX-DNA adducts. 
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Figure 3.2. Comparison of centroid structures. 
Structural alignment of the centroid structures using only the atoms from the DNA part of the 
molecule from the simulations of CP-DNA in AGGC and TGGA sequence contexts (A), OX-DNA 
in AGGC and TGGA sequence context (B) and CP- and OX-DNA in TGGA sequence context (C). 
The structural alignment of the central four base-pairs of the average structures of CP-DNA in 
AGGC and TGGA sequence contexts (D), OX-DNA in AGGC and TGGA sequence context (E) 
and CP- and OX-DNA in TGGA sequence context (F). Reproduced from Srinivas Ramachandran, 
Brenda R. Temple, Stephen G. Chaney and Nikolay V. Dokholyan, Structural basis for the 
sequence-dependent effects of platinum-DNA adducts. Nucleic Acids Research (2009) 
37(8):2434-2448, with permission from Oxford University Press. 
To further characterize the conformations sampled by CP- and OX-DNA adducts 
in the vicinity of platinum in the TGGA sequence context, we calculated the helical 
parameters of the central four base pairs of the dodecamer (T5G6G7A8) and the three 
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base-pair steps between them. With 6 parameters describing each base pair and 6 more 
for each base-pair step, there were a total of 42 helical parameters corresponding to the 
central four base pairs. We used the KS ratio (as described in Chapter 2) as a test for 
significant difference in comparing any two distributions of a particular helical parameter. 
To identify the parameters that showed major differences across different comparisons, 
we plotted the KS ratio of all the 42 parameters as a heat map. From the heat map, we 
selected the parameters that exhibited significant differences. When we compared the 
overall distributions of the helical parameters for CP-, OX- and undamaged DNA in the 
TGGA sequence context, both CP- and OX-DNA had significantly different 
conformations compared to undamaged DNA, especially in the G6-G7 base pair step, 
G6-C19 base pair and G7-C18 base pair (Figure 3.3). When comparing CP- and OX-
DNA, we observed differences in T5-G6 slide, A8-T17 buckle, T5-A20 opening and G6-
C19 opening (Figure 3.3). However, the differences between CP- and OX-DNA were 
minor, yielding KS ratios of  2. Thus, the CP- and OX-TGGA adducts appear to sample 
the same major DNA conformations when examined by this criteria. 
3.2. The pattern and frequency of hydrogen bond formation between 
the drug and DNA depend both on the sequence context and carrier 
ligand 
Earlier simulations in the AGGC sequence context had reported the formation of 
hydrogen bonds between platinum amines and adjacent bases (Sharma, et al., 2007), 
which correlated with minor conformational differences between CP- and OX-AGGC 
adducts that could influence the binding of HMGB1a to these adducts. We examined the 
trajectories of CP- and OX-TGGA adducts for hydrogen bond formation between all 
possible donors and acceptors using distance and angle criteria (as described in 
Chapter 2). In addition to the Watson-Crick hydrogen bonds in the DNA, we also 
observed the formation of hydrogen bonds between Pt-amines and adjacent base pairs. 
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When we compared the hydrogen bond patterns in the two sequence contexts, we 
observed that the bases involved and the frequency of formation of these hydrogen 
bonds were dictated both by the sequence context and the carrier ligand (Table 2.1). 
 
Figure 3.3. Conformational differences in overall distribution of helical parameters in the 
TGGA sequence context. 
The conformational differences in the central four base pairs between CP-, OX- and undamaged 
DNA in the TGGA sequence context are represented as a KS heat map of 3 possible 
comparisons; OX-DNA vs undamaged DNA, CP-DNA vs undamaged DNA and CP- vs OX-DNA. 
The KS ratio decreases in the order of Red > Blue > White in the heat map. 
In the AGGC sequence context, although the same hydrogen bonds were formed 
by both CP- and OX-Pt-amines, the frequency of hydrogen bond formation was 
different (Sharma, et al., 2007). The hydrogen bond to A5-N7 was formed more 
frequently for CP-DNA while the hydrogen bond to G7-O6 was formed more frequently 
for OX-DNA (Sharma, et al., 2007). In the TGGA sequence context, the G7-O6 
hydrogen bond was formed by both CP- and OX-DNA and like in AGGC sequence 
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context, the G7-O6 hydrogen bond was formed more frequently by OX-DNA (Table 2.1). 
Other hydrogen bonds seen in the TGGA sequence context were unique to either CP- or 
OX-DNA. OX-DNA formed hydrogen bonds on the 5’ side of the adduct, to T5-O3’ but 
only for a small fraction of time (6%, Table 2.1). On the 3’ side, CP formed hydrogen 
bond with A8-N7 with a frequency of 13% while OX formed hydrogen bonds with T17-O4 
with a frequency of 15%. These hydrogen bond patterns in the TGGA sequence context 
that were unique to CP- and OX-DNA adducts (A8-N7 for CP-DNA, T17-O4 and T5-O3’ 
for OX) all represented relatively minor conformations (occurring  15% of the time) of 
the Pt-DNA adduct.  
Table 3.1. Frequency of formation of different hydrogen bonds between Pt Ammines and 
adjacent bases.  
Reproduced from Srinivas Ramachandran, Brenda R. Temple, Stephen G. Chaney and Nikolay 
V. Dokholyan, Structural basis for the sequence-dependent effects of platinum-DNA adducts. 
Nucleic Acids Research (2009) 37(8):2434-2448, with permission from Oxford University Press. 
TGGA 
CP OXa 
Hydrogen bond 
type 
Frequency 
Hydrogen bond 
type 
Frequency 
G7-O6 32% G7-O6 55% 
A8-N7 13% T17-O4 15% 
  T5-O3’ 6% 
None 54% None 23% 
AGGCb 
CP OXc 
G7-O6 13% G7-O6 34% 
A5-N7 40% A5-N7 14% 
A5-N7+G7-O6 34% A5-N7+G7-O6 45% 
None 13% None 8% 
aOnly the equatorial hydrogen of the OX-amine was involved in 
hydrogen bonding on the 3’ side of the adduct bfrom ref.  cBoth 
equatorial and axial hydrogens of the OX-amine were involved in 
hydrogen bonds on the 5’ side, and only equatorial hydrogen of 
the OX-amine was involved in hydrogen bonding on the 3’ side 
of the adduct 
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3.4. Platinum amines in OX are more constrained compared to CP 
To determine the origin of differences between CP- and OX-DNA in the 
frequency of hydrogen bond formation with flanking bases on both sides of the Pt-GG 
adduct and their occupancy, we calculated the distributions of geometrical parameters of 
Pt from the simulations. As expected from the constraints imposed by the cyclohexane 
ring in OX, we observed that the 5’NHx-Pt-3’NHx bond angle had a significantly greater 
range for the CP-DNA adduct compared to the OX-DNA adduct (Figure 3.4) and the 
greater range for CP-DNA was observed in both TGGA and AGGC sequence contexts 
(data not shown). The 5’N7-Pt-5’NHx and the 3’N7-Pt-3’NHx bond angles also showed a 
slightly greater range for CP-DNA compared to OX-DNA (Figure 3.4). However, there 
was essentially no difference between CP- and OX-DNA in the 5’N7-Pt-3’N7 bond angle, 
presumably because of the constraints imposed by the DNA (Figure 3.4A). Thus, overall, 
CP-DNA was more flexible compared to OX-DNA with respect to the Pt-amines. The 
greater flexibility of CP compared to OX (especially with respect to the 5’NHx-Pt-3’NHx 
bond angle) may have resulted in the differences in local structure of the adduct, leading 
to differences in formation of hydrogen bonds between the drug and the adjacent bases. 
To further characterize the differences in the flexibility of CP-amines and OX-
amines, we examined the conformational flexibility of the N7-Pt-N-H dihedral angles for 
CP and OX on both 5’ and 3’ side of the adduct. The N7-Pt-N-H dihedral angle (Figure 
3.5A-C) determines the orientation of the amine hydrogens, which influences the ability 
of those hydrogens to form hydrogen bonds with the adjacent bases.  The N7-Pt-N-H 
dihedral angle for the CP-GG adduct has three broad peaks on both the 3’ and 5’ side of 
the adduct because all the hydrogens are equivalent and sample three different 
orientations. In contrast, the N7-Pt-N-H dihedral angle for OX has two relatively narrow 
peaks in distribution, with the one between -100º and -20º representing the equatorial 
hydrogen and the one between 20º and 80º representing the axial hydrogen in the 5’ 
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amine. The peaks are reversed for the 3’ amine. In both the AGGC sequence context 
(Figure 3.5D) and the TGGA sequence context (Figure 3.5E), the 3’N7-Pt-3’N-H dihedral 
angle positions the equatorial hydrogen of OX for the formation of the G7-O6 hydrogen 
bond, while the CP hydrogens are less frequently in the right orientation (compared to 
OX) for the formation of the G7-O6 hydrogen bond. Similarly in the TGGA sequence 
context, only the CP hydrogens spend a significant amount of time in a conformation 
favorable for the formation of the A8-N7 hydrogen bond and only the OX equatorial 
hydrogen spends a significant amount of time in a conformation favorable for the 
formation of the T17-O4 hydrogen bond (Figure 3.5E). Finally, in the AGGC sequence 
context, the 5’N7-Pt-N-H dihedral angle of CP allows one of the positions of the ammine 
hydrogens to be highly favorable for the formation of the A5-N7 hydrogen bond (Figure 
3.5F) while the equatorial hydrogen in 5’ side of OX has an orientation that is not as 
favorable as CP for the formation of the A5-N7 hydrogen bond. Thus, the allowable N7-
Pt-N-H dihedral angles (in part determined by the carrier ligand) provides a structural 
basis for the type and frequency of hydrogen bond formed in CP- and OX-DNA adducts 
in the TGGA and AGGC sequence contexts. 
3.5. Hydrogen bond formation is associated with distinctive 
distortions near the base to which the hydrogen bond is formed 
To examine if hydrogen bond formation correlated with unique conformations in 
the central 4 base pairs in the TGGA sequence context, we calculated the KS ratios for 
the helical parameters of the central four base pairs associated with the different 
hydrogen bonded species. For both CP- and OX-DNA, structures forming G7-O6 
hydrogen bond did not have major differences when compared to structures forming no 
hydrogen bonds to the Pt-amines (data not shown). However, we did observe significant 
differences when comparing the helical parameters of structures with CP-A8-N7  
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Figure 3.4. Geometrical parameters of platinum. 
The distributions of the four angles around the square-planar platinum atom are plotted from the 
CP- and OX-TGGA simulations: 5’N7-Pt-3’N7 (A), 5’NHx-Pt-3’NHx (B), 5’N7-Pt-5’NHx (C), 3’N7-
Pt-3’NHx (D). The Pt-amines at the 5’ and 3’ side of the adduct are denoted as 5’NHx and 3’NHx 
respectively. The N7s of G6 and G7 that are involved in covalent bonds with Pt are denoted as 
5’N7 and 3’N7 respectively. Reproduced from Srinivas Ramachandran, Brenda R. Temple, 
Stephen G. Chaney and Nikolay V. Dokholyan, Structural basis for the sequence-dependent 
effects of platinum-DNA adducts. Nucleic Acids Research (2009) 37(8):2434-2448, with 
permission from Oxford University Press. 
hydrogen bond to structures with the CP-G7-O6 hydrogen bond and in comparing 
structures with OX-T17-O4 hydrogen bond to structures with OX-G7-O6 hydrogen bond 
(Figure 3.6). From the KS ratio map of comparison of structures with the CP-A8-N7 
hydrogen bonds to the structures with the CP-G7-O6 hydrogen bond (Figure 3.6A), we 
observed the greatest differences in the G7-A8 base pair step, especially in rise, roll, 
shift, twist and slide parameters. Significant differences were also observed for G6-G7 
shift and G6-C19 opening. The parameters with major differences between structures 
with CP-A8-N7 hydrogen bond and all other species in CP-DNA yielded KS ratios of ~8-
15 indicating that the CP-A8-N7 hydrogen bonded species had a unique conformation 
compared to all other species in CP-DNA. Similarly, we observed from the KS ratio map 
of comparison of structures with OX-T17-O4 hydrogen bond to structures with OX-G7-
O6 hydrogen bond (Figure 3.6A) that the formation of OX-T17-O4 hydrogen bond 
resulted in unique conformations at G7-C18 base pair, G7-A8 base pair step and A8-T17 
base pair, as seen in G7-C18 shear, stagger and stretch; G7-A8 slide and A8-T17 
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buckle parameters. A significant difference was also observed for the G6-G7 twist. The 
same differences were also seen when the helical parameters were compared for 
structures with the OX-T17-O4 hydrogen bond to structures with no hydrogen bonds 
(data not shown). 
 
Figure 3.5. Dihedral angle involved in hydrogen bond formation. 
The dihedral angle describing the Pt-amine hydrogen orientation while forming hydrogen bond 
with adjacent DNA bases is shown for the G7-O6 hydrogen bond in CP-DNA in the AGGC 
sequence context (A), the A8-N7 hydrogen bond in CP-DNA in the TGGA sequence context (B) 
and the A5-N7 hydrogen bond in CP-DNA in the AGGC sequence context (C) respectively. 
Oxaliplatin has two hydrogens for each Pt-Ammine – equatorial (eq) and axial (ax). The 
distribution of the 3’N7-Pt-NHx-H dihedral angle is shown for the AGGC sequence context (D) and 
the TGGA sequence context (E). The distribution of the 5’N7-Pt-NHx-H dihedral angle is shown 
for the AGGC sequence context (F). Reproduced from Srinivas Ramachandran, Brenda R. 
Temple, Stephen G. Chaney and Nikolay V. Dokholyan, Structural basis for the sequence-
dependent effects of platinum-DNA adducts. Nucleic Acids Research (2009) 37(8):2434-2448, 
with permission from Oxford University Press. 
The distributions of helical parameters of the hydrogen-bonded species showing 
major differences in CP-DNA and OX-DNA are plotted in Figure 3.6B and Figure 3.6C, 
respectively. The G6G7A8 portion of the centroid structures forming the CP-A8-N7/OX-
T17-O4 hydrogen bond is compared with CP-G7-O6/OX-G7-O6 hydrogen bond in  
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Figure 3.6. Helical parameters in the TGGA sequence context. 
The conformational differences between two hydrogen-bonded species in all the 42 parameters 
are shown in a heat map (A). We represent the differences as the KS ratio, which is color-coded 
(The KS ratio decreases in the order of Red > Blue > White). Plots of histograms of the four 
helical parameters showing significant differences for different hydrogen bonded species of CP-
DNA adduct (B) and OX-DNA adduct (C), are shown. Alignment of 5’G6G7A8 3’ base pairs of the 
centroid structures forming the CP-G7-O6 hydrogen bond (red) and the CP-A8-N7 hydrogen 
bond (blue) (D) are shown. Alignment of 5’G6G7A8 3’ base pairs of the centroid structures 
forming the OX-G7-O6 hydrogen bond (red) and the OX-T17-O4 hydrogen bond (blue) (E) are 
also shown. The structures are aligned based on Pt-G6G7. Reproduced from Srinivas 
Ramachandran, Brenda R. Temple, Stephen G. Chaney and Nikolay V. Dokholyan, Structural 
basis for the sequence-dependent effects of platinum-DNA adducts. Nucleic Acids Research 
(2009) 37(8):2434-2448, with permission from Oxford University Press. 
Figure 3.6D and Figure 3.6E, respectively. In summary, we found that the 
formation of the minor hydrogen bonds on the 3’ flanking base pair in CP- and OX-DNA 
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was associated with unique conformations in the 3’ side of the adduct. We do not 
describe here the helical parameters of structures with T5-O3’ hydrogen bond in OX-
DNA since this hydrogen bond was formed only in 6% of the structures and because 
binding of HMGB1a to Pt-DNA is primarily through interactions on the 3’ side of the 
adduct. 
3.6. OX T17-O4 and CP A8-N7 are conformationally distinct with 
respect to the minor groove 
Formation of unique hydrogen bonds by CP- and OX-DNA to the drug suggested 
that these hydrogen-bonded species could represent structural differences between CP- 
and OX-DNA. When we compared structures forming the CP-A8-N7 hydrogen bond to 
structures forming the OX-T17-O4 hydrogen bond, we did observe significant 
differences. When seen facing the minor groove, the formation of CP-A8-N7 hydrogen 
bond shifted the A8-T17 base pair towards the left, while the formation of OX-T17-O4 
hydrogen bond shifted the A8-T17 base pair to the right (Figure 3.7A). Thus, the 
structural distortions associated with the formation of these hydrogen bonds are in 
opposite directions with reference to the minor groove.  Analyzing these differences 
quantitatively using helical parameters, we observed that the mean value of G7-A8 slide 
is -1 Å for the CP-A8-N7 hydrogen bond, while it is +1.8 Å for the CP-T17-O4 hydrogen 
bond (Figure 3.7B). Similarly, the shift, twist and roll of the G7-A8 base pair step are 
clearly different for structures with CP-A8-N7 hydrogen bond compared to those with the 
OX-T17-O4 hydrogen bond (Figure 3.7B). As might be expected, these conformational 
differences correlated with the T17-O4 atom being closer to the Pt-amine hydrogen of 
OX and the A8-N7 atom being closer to the Pt-amine hydrogen of CP. In summary, 
when comparing CP-DNA to OX-DNA, the minor conformations had distinct distributions 
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of helical parameters in the vicinity of hydrogen bond formation that were unique to 
either CP- or OX-DNA.  
 
Figure 3.7. Differences in DNA conformation and helical parameters of A8-N7 and T17-O4 
hydrogen bonded species in CP- and OX-DNA respectively. 
(A) Alignment of the 5’G6G7A8 3’ base pairs of the centroid structures forming A8-N7 hydrogen 
bond in CP-DNA adduct and the T17-O4 hydrogen bond in the OX-DNA adduct is shown. The 
structures are aligned based on Pt-G6G7. (B) Plots of histograms of the four helical parameters 
showing greatest differences between the A8-N7 hydrogen bonded species in CP-DNA and T17-
O4 hydrogen bonded species in OX-DNA are shown. The distributions of twist, slide, roll and shift 
parameters of the G7-A8 base-pair step are plotted because the greatest differences are in this 
base-pair step (data not shown). The solid line represents distribution of structures with CP-A8-
N7 hydrogen bond while the dashed line represents distribution of structures with OX-T17-O4 
hydrogen bond. The frequency distributions are calculated and normalized as described earlier. 
Reproduced from Srinivas Ramachandran, Brenda R. Temple, Stephen G. Chaney and Nikolay 
V. Dokholyan, Structural basis for the sequence-dependent effects of platinum-DNA adducts. 
Nucleic Acids Research (2009) 37(8):2434-2448, with permission from Oxford University Press. 
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3.7. Conclusions 
Our simulations of Pt-DNA in the TGGA sequence context provide the first 
glimpse of distinct conformations sampled by CP- and OX-DNA. Our extensive 
simulations show little differences between the major conformations sampled by CP- and 
OX-DNA, which agrees well with data from X-ray crystallography in the TGGT sequence 
context and NMR spectroscopy in the AGGC sequence context. However, we also 
report distinct hydrogen bonds in CP- and OX-DNA formed between Pt-amines and the 
base pairs adjacent to the GG-adduct. The distinct hydrogen bonds correlate with 
distinct conformations on the 3’ side of the adduct. Here, it is important to note that we 
cannot determine if it is the hydrogen bonds that drive distinct conformations. However, 
these hydrogen bonds offer a unique signature that is used to separate minor 
conformations in our simulation ensemble. The fact that these hydrogen bonded species 
have specific conformational characteristics underscores the robustness of using Pt-
amine-DNA hydrogen bonds to uncover minor conformations. In summary, we find that 
indeed, it is the conformational dynamics and the minor conformations sampled by CP- 
and OX-DNA that differentiate the adducts in the TGGA sequence context. These 
conformational differences, especially on the 3’ side of the adduct might be important in 
differential binding affinity of HMGB1a, since the protein’s binding mode to Pt-DNA 
orients it to the 3’ side of the adduct. In subsequent chapters, we will explore the effect 
of these conformational differences in protein recognition and binding. 
Chapter 4. Effect of sequence context on the 
conformational dynamics of Pt-DNA adducts 
The sequence dependence on the extent of  differential binding of proteins to 
CP- and OX-DNA (Table 3.1) suggests sequence context dependent differences in 
structural distortions caused by CP- and OX-GG adducts. Even though DNA by itself has 
several sequence dependent structural features that are exploited by proteins that bind 
DNA in a sequence dependent manner, the presence of Pt adduct bestows additional 
interactions and distortions, the extent of which could depend on the bases flanking the 
Pt-GG adduct. MD simulations on CP- and OX-DNA adducts performed in an identical 
manner in three different sequence contexts allows us to compare the effect of both 
carrier ligand and sequence context on the conformational dynamics of DNA.  
4.1. DNA conformation in the vicinity of the Pt-GG adducts 
In the context of the undamaged DNA, TGGA and TGGT sequences would be 
expected to have similar conformations in the 5’ side of the GG adduct, while AGGC 
sequence will have some unique conformational signatures. On the 3’ side, TGGA is 
more different than AGGC and TGGT because of a purine on the 3’ side of the adduct 
as opposed to pyrimidines in the other sequences. The differences in the undamaged 
DNA could either be maintained in Pt-DNA or be overtaken by the distortions due to Pt-
adduct. Additionally, sequence dependent differences can arise in Pt-DNA that were not 
seen in undamaged DNA.  
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To understand the effect of Pt adduct and the sequence context on DNA 
conformation near the adduct, we compared the helical parameters corresponding to the 
central four base-pairs from our simulations in the TGGA, TGGT and AGGC sequence 
context. We observed significant differences between the three sequences in either 
undamaged or CP- or OX-DNA in 17 of the 42 helical parameters, indicating large-scale 
conformational dependence on sequence context (with or without the drug). We further 
classify these parameters into four groups that are characterized by:  
Group 1: Differences that are consistent across undamaged, CP- and OX-DNA  
Group 2: Differences in undamaged DNA that are suppressed by the presence of Pt 
adduct 
Group 3: Differences that are brought about due to the presence of Pt adduct, and may 
be specific to CP- or OX-DNA 
Group 4: Differences that can be predominantly explained as due to the occurrence of 
hydrogen bonds between Pt-amines and adjacent DNA bases 
The ability to define these groups allows us to delineate sequence-dependent 
effects (Group 1), Pt-dependent effects (Group 2), carrier ligand dependent effects 
(Group 3) and effects dependent on both carrier ligand and sequence context (Group 4). 
We will discuss the conformational parameters that fall into these groups next. 
Group1.  The differences in the group are in the 5’ side of the adduct and AGGC 
sequence is observed to be different compared to TGGA and TGGT sequences that are 
similar to each other. Thus, the sequence dependent changes in undamged DNA by 
having and adenine compared to thymine on the 5’ side of the adduct are maintained in 
5-20 buckle, 5-6 roll and 5-6 tilt. AGGC sequence features mean positive buckle, while 
TGGA and TGGT sequences feature mean negative buckle in the base-pair 5’ to the 
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adduct (Figure 4.1). The similar trend is maintained in the presence of CP and OX 
adducts. Similarly, the roll on the 5’ base-pair step is lower in AGGC compared to TGGA 
and TGGT (Figure 4.1), while AGGC features a mean negative tilt compared to TGGA 
and TGGT sequences. No such significant differences were seen in the 3’ side of the 
adduct. 
Group 2. Similar to Group1, AGGC sequence in the undamaged DNA is different 
to TGGA and TGGT sequences in 5-6 shift, rise and twist, 6-7 shift and 8-17 propel. 
However, in the presence of Pt-adduct, these significant differences in undamaged DNA 
disappear, imposing a homogeneity in these helical parameters (Figure 4.2). 
 
Figure 4.1. Helical parameters having similar trends in undamaged, CP- and OX-DNA when 
compared across AGGC, TGGA and TGGT sequence contexts.  
Not shown here are the distributions for 5-6 tilt. 
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Figure 4.2. Helical parameters in which the sequence-specific conformation in undamaged 
DNA is suppressed in CP- and OX-DNA.  
Group 3. This group is characterized by helical parameters that show no 
significant difference in undamaged DNA, but presence of CP and OX adducts 
induces sequence-specific changes. These changes are either similar in CP and OX or 
are carrier ligand specific. Thus, this group signifies Pt and carrier ligand specific 
conformation in a given sequence. We observe this trend in 5-20 propeller twist, 6-19 
buckle and propeller twist, 7-18 buckle, stagger and propeller twist, and 7-18 stagger. 5-
20 propeller twist illustrates this group well: AGGC has a lower 5-20 propeller twist in 
both CP- and OX-DNA, while TGGT sequence has lower 5-20 propeller twist in CP-
DNA. TGGA features uniform values for the 5-20 propeller twist. Other parameters also 
feature similar differences that are specific for CP- and OX-DNA, with some examples 
shown in Figure 4.3.  
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Figure 4.3. Helical parameters in which the presence of Pt-adduct induces differences 
between different sequences, which may be carrier ligand specific. 
 
Group 4. This group is a subset of Group 3, but here we know that the sequence 
and carrier ligand specific conformations are accompanied by hydrogen bonding 
between Pt-amine and the adjacent base. There are only two parameters where these 
differences show up: 5-6 slide and 7-8 slide. Hydrogen bonding between A5 and 5’ Pt-
amine leads to negative values of 5-6 slide in the CP- and OX-DNA in the AGGC 
sequence context compared to TGGA and TGGT sequence context, where the value of 
this parameter in Pt-DNA mirrors closely to undamaged DNA. CP-DNA in TGGT 
sequence context has a shoulder at positive values of the slide, which does represent a 
minor conformation, but this conformation is not accompanied by any specific hydrogen 
bond. In the TGGA sequence context, as seen in Chapter 3, CP- and OX-DNA form 
distinct hydrogen bonds with the 3’ flanking base-pair – CP-DNA forms the A8N7 
hydrogen bond, while OX-DNA forms the T17O4 hydrogen bond. Also, as seen in 
Chapter 3, the formation of these hydrogen bonds lead to a positive value of the 7-8 
slide in OX-DNA and a negative slide in the CP-DNA. These minor conformations skew 
the overall distribution of the 7-8 slide in opposite directions in CP- and OX-DNA with 
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respect to the other sequences. AGGC on the other hand shows a more negative slide 
in undamaged DNA, but is quite similar to the TGGT sequence in Pt-DNA (Figure 4.4). 
 
Figure 4.4. Helical parameters showing sequence-specific conformations in Pt-DNA that 
are accompanied by hydrogen bonding between Pt-amine and base-pair adjacent to the Pt-
GG adduct. 
4.2. Hydrogen bond formation between Pt amines and adjacent base-
pairs 
In chapter 3, we discussed the formation of hydrogen bonds between Pt-amines 
and adjacent bases in our simulations of Pt-DNA. These hydrogen bonds are observed 
in all three sequence contexts we have performed simulations with (AGGC, TGGA, 
TGGT). In the TGGT sequence context, we observe two types of hydrogen bonds 
formed between Pt-amines and DNA in both CP- and OX-DNA. The hydrogen bond 
between the 3’ Pt-amine and the O6 atom of the 3’ Guanine (the G7-O6 hydrogen bond) 
is formed more frequently by OX-DNA (72% of the time compared to 32% by CP-DNA, 
Table 4.1), while the hydrogen bond between the 3’ amine and the O4 atom of 3’ 
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Thymine (the T8-O4 hydrogen bond) is formed more frequently by CP-DNA (49% 
compared to 19% by OX-DNA). When we consider the hydrogen bond patterns from 
three different sequence contexts and two carrier ligands, we observe both carrier ligand 
and sequence-specific differences (Table 4.1). 
Table 4.1. Frequency of formation of different hydrogen bonds between Pt Ammines and 
adjacent bases 
TGGT 
CP OXa 
Hydrogen bond 
type 
Frequency 
Hydrogen bond 
type 
Frequency 
G7-O6 20% G7-O6 59% 
T8-O4 37% T8-O4 6% 
T8-O4+G7-O6 12% T8-O4+G7-O6 13% 
None 29% None 20% 
TGGA 
CP OXa 
G7-O6 32% G7-O6 55% 
A8-N7 13% T17-O4 15% 
  T5-O3’ 6% 
None 54% None 23% 
AGGCb 
CP OXc 
G7-O6 13% G7-O6 34% 
A5-N7 40% A5-N7 14% 
A5-N7+G7-O6 34% A5-N7+G7-O6 45% 
None 13% None 8% 
 
The first carrier ligand specific trend we observe is that the formation of a 
hydrogen bond between the 3’ Pt-amine and G7-O6 (O6 atom of the 3’ Guanine in Pt-
GG) occurs more frequently for OX-DNA adducts than for CP-DNA adducts in all three 
42 
sequence contexts. This trend is mainly due to the hydrogens of Pt-amines in OX being 
locked in an orientation most favorable for the formation of the G7-O6 hydrogen bond, 
while those in CP are free to move, spending much lesser time in the orientation 
required for the G7-O6 hydrogen bond (Figure 3.5). The second carrier ligand specific 
effect we observe is that the ease of formation of hydrogen bonds between Pt-amines 
and bases adjacent to the GG adduct (the 5’A in the AGGC sequence context and the 
3’T or 3’A in the TGGT and TGGA sequence contexts) is higher for CP-DNA adduct 
compared to the OX-DNA adduct.  Presumably, this effect is also the consequence of 
the constraints placed on the amine by the cyclohexane ring of OX.  
In terms of sequence-specific effects, we observe that significant frequency of 
hydrogen bonding on the 5’ side of the adduct occurs only in the AGGC sequence 
context (the A5-N7 hydrogen bond). Given the structural characteristics of a double 
helix, only the N7 atoms of adenine and guanine are accessible for hydrogen bond 
formation by the 5’ Pt-ammine and  no significant hydrogen bonding is seen when the 5’ 
base is thymine. Apart from the G7-O6 hydrogen bond, similar hydrogen bonds are 
formed by Pt-amines to the adjacent bases in AGGC and TGGT sequence contexts. 
However, in the TGGA sequence context, the hydrogen bond formed by the Pt-amine 
(other than G7-O6) is unique to CP- and OX-DNA. CP-DNA forms the A8-N7 hydrogen 
bond on the 3’ side of the adduct. OX-DNA cannot form a hydrogen bond with A8-N7, 
but is able to form a hydrogen bond with O4 of the thymine on the opposite strand. The 
distinct hydrogen bonds formed in the TGGA sequence context correlate with the 
highest differences in differential binding affinities for CP- and OX-GG adducts by 
HMGB1a, HMGB1b and TBP(Wei, et al., 2001). Thus, we observe that the hydrogen 
bond formation significantly correlates with the pronounced sequence dependent effects 
of Pt-DNA adducts as observed from MD simulations and may point to minor 
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conformations of Pt-DNA adducts that influence the recognition of the adducts by DNA 
binding proteins. 
4.3. Conclusions 
From our comparison of DNA conformation in the vicinity of the Pt-GG adduct, 
we can conclude that the conformation of CP- and OX-GG adducts depend a lot on the 
flanking bases. We observed several helical parameters being influenced in a carrier-
ligand and sequence dependent manner. These conformational differences could be the 
origin of the observed sequence dependence in binding of proteins and the efficiency of 
translesion polymerases. Specifically, most of the distinct conformations in the 5’ side 
are seen in the AGGC sequence context, while many differences in the 3’ side are seen 
in both TGGT and TGGA sequence contexts. The formation of sequence-dependent 
hydrogen bonds by Pt-amines reflect not only the differences in the electron donor in the 
bases adjacent to the Pt-GG adduct, but also the difference in flexibility that leads to 
hydrogen bonds either on the 5’ side or the 3’ side of the adduct. Finally it is worth noting 
that several sequence dependent structural features of undamaged DNA are 
suppressed by the formation of Pt-GG adduct, indicating the overwhelming structural 
distortion induced by Pt. 
 
Chapter 5. Interaction of HMGB1a with Pt-DNA 
As elaborated in Chapter 1, differential binding of CP- and OX-DNA to HMG-
domain proteins could be an important facet of differential efficacies of CP and OX in 
different tumors. More importantly, HMG-domain proteins have been shown to play 
important role in Pt drug sensitivity. HMGB1 is one of the first identified proteins to bind 
to Pt-DNA adducts and hence has been characterized in detail. Furthermore, the crystal 
structure of HMGB1a-Pt-DNA is available only for CP-DNA in the TGGA sequence 
context (PDB ID 1CKT (Ohndorf, et al., 1999)). To uncover the basis for differential 
binding affinity, structural data is required for both CP- and OX-DNA binding to 
HMGB1a. In this scenario, MD simulations are able to provide structural details of 
HMGB1a binding to both CP- and OX-DNA. We performed three sets of simulations of 
50 ns each of the complex between HMGB1a and Pt-DNA in three sequence contexts 
(TGGA, TGGT and AGGC) and with two drugs (CP and OX). With these simulations, our 
goal was to uncover the molecular basis of ~53 fold difference in binding affinity between 
CP- and OX-DNA in the TGGA sequence context and also the sequence dependent 
interactions of HMGB1a with Pt-DNA. We observed that these simulations showed 
uniform RMSD fluctuations after about five nanoseconds; hence we utilized the final 45 
ns of all the trajectories for various structural analysis. 
5.1. DNA conformational parameters that influence HMGB1a binding 
We have discussed that one of the most important determinants of HMGB1a 
binding was the effective intercalation of Phe37 between the platinated GG basepair 
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step. Additionally, it is known that HMGB1a binds efficiently to bent DNA, in fact the 
binding affinity of HMGB1 to DNA minicircles is similar to that of Pt-DNA (Webb, et al., 
2001). The crystal structure of HMGB1a-Pt-DNA also revealed a hydrogen bond 
between Ser41 in HMGB1a and the base 5’ to the Pt-GG adduct. Finally, the crystal 
structure revealed multiple interactions between the HMGB1a binding interface and the 
minor groove of Pt-DNA. The conformation of DNA plays an important role in 
determining the efficiency of the Phe37 intercalation, Ser41 hydrogen bond and efficient 
bending of DNA by HMGB1a binding, which provides a wide and shallow minor groove 
suitable for interacting with HMGB1a binding interface. Thus, in this section we will 
analyze the conformation of bound and free Pt-DNA in the context of these three 
parameters. 
5.1.1. Conformations favoring Phe37 stacking 
Binding of HMB1a to Pt-DNA involves the intercalation of Phe37 in the platinated 
base-pair step, resulting in the roll of this base-pair step being 56.7º (Ohndorf, et al., 
1999). Thus, ability to sample higher roll could result in better binding affinity of Pt-DNA. 
The G6-G7 base pair step has a mean roll of 3.3º and 5.3º in undamaged DNA in the 
TGGA and AGGC sequence contexts respectively. The formation of either CP- or OX-
G6G7 adducts shifted the G6-G7 roll to significantly higher values compared to 
undamaged DNA (Figure 5.1). There was also a pronounced shoulder in the 
distributions of G6G7 roll parameters in Pt-DNA adducts in both TGGA and AGGC 
sequence contexts (Figure 5.2). This shoulder lies in the region that is favorable for 
binding of HMGB1a, and differs between CP- and OX-GG adducts to different extents in 
different sequence contexts. In the TGGA sequence context, the CP-GG adduct 
explored conformations with G6G7 roll ±10º of the roll of CP-DNA bound to HMGB1a 3.2 
times more frequently than OX-GG adducts, while in the AGGC sequence context, CP- 
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and OX-GG adducts explored rolls within ±10º of the roll of CP-DNA bound to HMGB1a 
to about the same extent. The distributions with higher roll were mainly comprised of 
structures forming the CP-A8-N7 hydrogen bond in the TGGA sequence context (Figure 
5.2), while in the AGGC sequence context, the regions of high roll were associated 
mainly with the formation of both CP- and OX-A5-N7 hydrogen bond (Figure 5.2). Thus, 
hydrogen bonding to adjacent adenine in both sequence contexts was associated with 
higher roll in the G6G7 base pair step. 
 
Figure 5.1. Distribution of the G6-G7 roll.  
The distribution of G6-G7 roll, which is important for intercalation of Phe37 of HMGB1a between 
the G6-G7 base pair step is plotted for the AGGC and the TGGA sequence contexts. The 
distributions of CP-, OX- and undamaged DNA are plotted in each sequence context. The bend 
angle of DNA in the crystal structure of CP-DNA bound to HMGB1a(Ohndorf, et al., 1999) is 
plotted as a vertical dashed line. The region of roll ±10º of the roll in the crystal structure of CP-
DNA bound to HMGB1a is plotted alongside to highlight differences between CP- and OX-DNA in 
the TGGA sequence context. Reproduced from Srinivas Ramachandran, Brenda R. Temple, 
Stephen G. Chaney and Nikolay V. Dokholyan, Structural basis for the sequence-dependent 
effects of platinum-DNA adducts. Nucleic Acids Research (2009) 37(8):2434-2448, with 
permission from Oxford University Press. 
The difference between CP- and OX-DNA in the roll of the G6-G7 base-pair step 
may be significant for HMGB1a binding to Pt-DNA adducts.  Ohndorf et al (Ohndorf, et 
al., 1999) have shown that the crystal structure of the HMGB1a-CP-DNA complex has 
significantly greater roll (56.7º) at the platinated GG base pair step than free CP-DNA 
and have postulated that the greater roll enables ideal geometry for - stacking of  
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Figure 5.2. G6-G7 roll parameter of different hydrogen bonded species in CP- and OX-DNA 
adducts in the TGGA and AGGC sequence contexts. 
The distribution of G6-G7 roll of different hydrogen-bonded species in CP-TGGA, OX-TGGA, CP-
AGGC and OX-AGGC are plotted. The left panel shows the distribution for the whole range of roll 
values, while the right panel is zoomed into the distributions at roll > 40°. 
Phe37 of HMGB1a with the 3’ Guanine of the platinated base-pair step. This interaction 
appears to be particularly important for the stability of the HMGB1a-Pt-DNA complex, 
since the Phe37Ala mutation reduces binding affinity >667-fold. The ability of free CP-
DNA in the TGGA sequence context and both free CP- and OX-DNA in the AGGC 
sequence context (but not free OX-DNA in the TGGA sequence context) to sample roll 
at values seen in the crystal structure of the HMGB1a-CP-DNA complex would suggest 
that these Pt-DNA adducts have the conformational flexibility to readily form the 
HMGB1a-Pt-DNA complex. In contrast, OX-TGGA alone samples lower roll angles at the 
platinated base-pair step, suggesting that it would have more difficulty forming a 
complex that has optimal stacking of Phe37 to the 3’G. As expected, our simulations of 
the HMGB1a complexes with Pt-DNA show that indeed the mean platinated base-pair 
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roll of OX-TGGA is downshifted by ~3.2º compared to the roll seen in CP- and OX-
AGGC and CP-TGGA and in the crystal structure of the HMGB1a-CP-DNA complex 
(Figure 5.3). 
 
Figure 5.3. Distributions of the Pt-GG roll in the HMGB1a-Pt-DNA simulations. 
The distribution of the roll of the Pt-GG base-pair step, which is important for stacking of Phe37 of 
HMGB1a to the 3’G is plotted for the HMGB1a-Pt-DNA complexes in the AGGC and the TGGA 
sequence contexts. The dashed vertical line represents the roll of the G6-G7 base pair step from 
the HMGB1a-CP-DNA crystal structure. Reproduced from Srinivas Ramachandran, Brenda R. 
Temple, Stephen G. Chaney and Nikolay V. Dokholyan, Structural basis for the sequence-
dependent effects of platinum-DNA adducts. Nucleic Acids Research (2009) 37(8):2434-2448, 
with permission from Oxford University Press. 
In summary, CP-DNA in the TGGA sequence context was able to sample 
conformations that resulted in a high roll in the G6G7 base pair step, which has been 
suggested to favor binding to HMGB1a (Ohndorf, et al., 1999), while OX-DNA in the 
same sequence context was unable to sample these conformations. Contrastingly, both 
CP- and OX-DNA sampled conformations with a high roll in the G6G7 base pair step to 
the same extent in the AGGC sequence context. Furthermore, these differences in roll 
between CP- and OX-DNA adducts in the TGGA sequence context appear to be 
preserved in the complexes with HMGB1a. 
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5.1.2. Overall bend angle 
HMGB1a, whose differential binding affinity to CP- and OX-DNA has been 
experimentally characterized (Malina, et al., 2007; Pil and Lippard, 1992), binds 
specifically to bent or distorted DNA and bends it further (Bianchi, et al., 1989; Pil, et al., 
1993). The formation of the Pt-GG adduct induces a sharp bend in the DNA towards the 
major groove and results in the formation of a wide and shallow minor groove which 
provides multiple sites for interaction with HMGB1a (Ohndorf, et al., 1999). The higher 
bend angle of the Pt-DNA adduct has been postulated to make the binding of HMGB1a 
to Pt-DNA energetically more favorable compared to undamaged DNA (Pil, et al., 1993), 
and hence the distribution of the bend angles could influence the preferential binding of 
HMG-domain proteins to Pt-DNA. 
We first examined the propensity of free Pt-DNA to bend. We calculated the 
overall bend angle of the central 10 base pairs of the different hydrogen-bonded 
conformations using the program MADBEND (Strahs and Sclick, 2000). The overall 
distribution of bend angles indicated that the platinated DNA is more bent than 
undamaged DNA as expected (Figure 5.4). When we compared CP- and OX-GG 
adducts in the TGGA sequence context, we observed a higher population of structures 
in CP-GG adduct compared to OX-GG adduct having bend angles close to 58.9º, which 
is the bend angle of CP-DNA bound to HMGB1a found in its crystal structure (Ohndorf, 
et al., 1999) (represented as a dashed vertical line in Figure 5.4). When we computed 
the percentage of species having bend angles ±10º of the bend angle of CP-DNA bound 
to HMGB1a, we found that CP-GG had 10.25% of the population in this region, while 
OX-GG adduct had only 5.86% of its population in this region. The situation was 
reversed in the AGGC sequence context, where OX had 22.15% of the population within 
±10º of the bend angle of CP-DNA bound to HMGB1a (in its crystal structure (Ohndorf, 
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et al., 1999)), while CP-GG adduct had only 15.24% of the population in the higher bend 
angle region of the distribution. 
 
Figure 5.4. Bend angle distributions of CP-, OX- and undamaged DNA 
The bend angle distributions of CP-, OX-GG adducts and undamaged DNA in the TGGA and the 
AGGC sequence context are plotted. The bend angle of DNA in the crystal structure of CP-DNA 
bound to HMGB1a(Ohndorf, et al., 1999) is plotted as a vertical dashed line. The region of bend 
angle ±10º of the bend angle in the crystal structure of CP-DNA bound to HMGB1a is plotted 
alongside to highlight differences between CP- and OX-GG adducts. Reproduced from Srinivas 
Ramachandran, Brenda R. Temple, Stephen G. Chaney and Nikolay V. Dokholyan, Structural 
basis for the sequence-dependent effects of platinum-DNA adducts. Nucleic Acids Research 
(2009) 37(8):2434-2448, with permission from Oxford University Press. 
Upon clustering the distribution of bend angles based on hydrogen bond 
formation, we observed significant correlation between hydrogen bond pattern and bend 
angle (Figure 5.5). In the TGGA sequence context, the A8-N7 hydrogen bond formed by 
the CP-GG adduct was associated with higher bend angles (mean bend angle of 44.3º) 
compared to species with no hydrogen bonds (29.8º) and with the G7-O6 hydrogen 
bond (29.9º). For the OX-GG adduct, no single species stood out with higher mean bend 
angle. In the AGGC sequence context, the formation of A5-N7 hydrogen bond was 
associated with a higher bend angle compared to the structures with the G7-O6 
hydrogen bond or no hydrogen bonds with the drug for both CP- and OX-GG adducts. In 
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summary, higher bend angles were associated with hydrogen bond formation to 
adjacent adenines in both TGGA and AGGC sequence contexts, which gave a 
significant advantage to the CP-GG adduct in the TGGA sequence context and a slight 
advantage to the OX-GG adduct in the AGGC sequence context in terms of interaction 
with HMGB1a.  
 
Figure 5.5. Bend Angle distributions of hydrogen-bonded species in the TGGA and AGGC 
sequence contexts. 
The bend angle distributions of different hydrogen-bonded species in CP-TGGA, OX-TGGA, CP-
AGGC and OX-AGGC are plotted. The frequency distribution for a particular hydrogen bonded 
species was obtained from structures that formed that particular hydrogen bond. However, the 
normalization was performed over the total number of structures (30,000 structures for Pt-DNA in 
the TGGA sequence context and 60,000 structures for Pt-DNA in the AGGC sequence context) to 
show the relative abundance of different hydrogen bonded species. The bend angle of DNA in the 
crystal structure of HMGB1a bound to CP-DNA is shown as a dashed vertical dashed line. 
To examine if the behavior of free Pt-DNA in terms of the bend angle was 
predictive of the HMGB1a-Pt-DNA complex, we analyzed the bend angles calculated 
from the HMGB1a-Pt-DNA simulations in the three sequence contexts (Figure 5.6). We 
observe little difference in bend angles of CP- and OX-DNA in the TGGA sequence 
context, with distribution of CP-DNA having slightly higher values at higher bend angles. 
In the HMGB1a-Pt-DNA complex, this subtle difference in the bend angle distribution 
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may not translate to much better binding. However, in TGGT and AGGC sequence 
context, we observe that the distribution of bend angles of CP-DNA is slightly right-
shifted compared to OX-DNA, which may indicate better binding by CP-DNA in these 
sequences. 
 
Figure 5.6. Bend angle distributions of CP-, OX-DNA bound to HMGB1a 
The bend angle distributions of CP-, OX-GG adducts and undamaged DNA in the TGGA and the 
AGGC sequence context are plotted. The distribution for undamaged DNA is plotted as a solid 
line; the distribution for CP-DNA is plotted as a dotted line and that for OX-DNA is plotted as a 
dashed line. The bend angle of DNA in the crystal structure of CP-DNA bound to 
HMGB1a (Ohndorf, et al., 1999) is plotted as a vertical dashed line. 
5.1.3. Conformations favoring Ser41 Hydrogen bond  
In the crystal structure of the HMGB1a-CP-DNA complex in the TGGA sequence 
context, Ser41 of HMGB1a forms a hydrogen bond with N3 atom of the adenine 3’ to Pt-
GG adduct(Ohndorf, et al., 1999) (which would correspond to A8 in our simulations of 
free Pt-DNA). Mutagenesis experiments suggest that this hydrogen bond has a minor 
(~4-fold) effect on the affinity of HMGB1a for CP-DNA(He, et al., 2000). In our HMGB1a-
Pt-DNA simulations, surprisingly, we observe hydrogen bond between S41 and the base 
3’ to the Pt-GG adduct regardless of the identity of the 3’ base or the Pt-drug (Table 5.1). 
When we calculated the energetic contribution of this hydrogen bond seen in our MD 
simulations using an orientation dependant hydrogen bonding potential(Ding and 
Dokholyan, 2006), we observe the mean hydrogen-bond energy due to the Ser41-A 
hydrogen bond in the CP-HMGB1a complex is 0.78 kcal/mol ± 0.003 (S.E.M), which 
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compares well with 0.832 kcal/mol observed experimentally (S41A mutation causes four-
fold increase in binding dissociation constant) (Table 5.1, Figure 5.7). OX-HMGB1a 
features the same hydrogen bond of similar energy. However, the TGGT and AGGC 
sequence contexts feature pyrimidines in the 3’ side of the adduct, and hence a SP2 
hybridized oxygen (O2). We observe these oxygens to form hydrogen bonds with S41 in 
our simulations and further, they are almost twice more stabilizing compared to the 
TGGA sequence context (Table 5.1, Figure 5.7). Thus, we observe S41 forming 
sequence specific hydrogen bonds with Pt-DNA. 
Table 5.1. Summary of hydrogen bond formation between Ser41 and the base 5’ to the Pt-
GG adduct 
Sequence 
Context 
Hydrogen 
Bonding 
Atom 
Drug 
% 
Occupancy 
Mean Hydrogen 
Bond Energy 
(kcal/mol) 
CP 89 1.44 
AGGC C-O2 
OX 83 1.40 
CP 63 0.99 
TGGT T-O2 
OX 80 1.28 
CP 70 0.79 
TGGA A-N3 
OX 79 0.87 
 
 
Figure 5.7. Distribution of the strength of hydrogen bond between Ser41 and the base 3’ to 
Pt-GG adduct.  
The hydrogen bond strength (energy) was calculated using an orientation dependent hydrogen 
bond potential for CP- and OX-DNA in TGGA, AGGC and TGGT sequence contexts. 
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In the HMGB1a-Pt-DNA complexes (in TGGA sequence context), the structures 
forming the Ser41-A8 hydrogen bond have a G7-A8 slide and twist that is intermediate 
between that observed in the minor conformations of the free CP- and OX-DNA 
ensembles. However, the HMGB1a-Pt-DNA conformers containing the Ser41-A8 
hydrogen bond have a G7-A8 roll of 0-7.5º and a G7-A8 shift of -1 to 0 , which is very 
close to the conformation of the G7-A8 base-pair step seen in structures with T17-O4 
hydrogen bond in free Pt-DNA simulations (Figure 5.8).  
 
Figure 5.8. Comparison of G7-A8 base-pair step parameters between free and protein 
bound Pt-DNA in the TGGA sequence context. 
Twist, slide, roll and shift parameters of the G7-A8 base-pair step are plotted for structures with 
CP-A8-N7 hydrogen bond, OX-T17-O4 hydrogen bond, CP- HMGB1a-Ser41-A8-N3 and OX-
HMGB1a-Ser41-A8-N3 hydrogen bond. The frequency distribution for a particular hydrogen 
bonded species was obtained from structures that formed that particular hydrogen bond. 
However, the normalization was performed over the total number of structures (30,000 structures 
for free Pt-DNA and 45,000 for HMGB1a bound Pt-DNA) to show the relative abundance of 
different hydrogen bonded species. To enable comparison of free and bound Pt-DNA (which 
differ in sampling by an order of magnitude) in the same graph, we employ two Y-axes, which are 
color-coded. Reproduced from Srinivas Ramachandran, Brenda R. Temple, Stephen G. Chaney 
and Nikolay V. Dokholyan, Structural basis for the sequence-dependent effects of platinum-DNA 
adducts. Nucleic Acids Research (2009) 37(8):2434-2448, with permission from Oxford University 
Press. 
Thus, structures with the OX-T17-O4 hydrogen bond in free Pt-DNA would aid 
the formation of Ser41 hydrogen bond during complex formation, while structures with 
CP-A8-N7 hydrogen bonds have the A8 in a position unfavorable for hydrogen bonding 
with Ser41 during binding to HMGB1a. The Ser41 occupancy in CP- and OX-DNA in the 
TGGA sequence context indeed support this prediction from free Pt-DNA; the Ser41 
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hydrogen bond is observed 79% of the time in complex with OX-DNA compared to 70% 
in the complex with CP-DNA, resulting in the Ser41 hydrogen bond in the complex with 
OX-DNA being stronger than in complex with CP-DNA on average(0.87 kcal/mol 
compared to 0.79 kcal/mol). 
5.2. The HMGB1a-Pt-DNA interface 
We next analyze the differences in protein-DNA interface between HMGB1a-CP- 
and HMGB1a-OX-DNA in the TGGA sequence context, where the largest difference in 
binding affinity is observed experimentally. It is important to note that, in these 
comparisons, the only difference lies in the carrier-ligand of the drug, which is not even a 
part of the protein-DNA interface. We use two complementary measures to analyze the 
interface. The first is the total number of contacts across the protein-DNA interface. We 
define a contact as any two non-hydrogen atoms being within a distance of 5 Å. Since 
our force fields are pairwise additive, the number of contacts would be a reliable 
predictor of the strength of the overall core/interface. Secondly, we analyze contacts 
between individual protein residue and DNA base. These comparisons also rely on the 
number of contacts between the residue and the base, but provide information at a 
resolution higher than that of total number of interface contacts. Furthermore, the 
number of contacts between individual residue and base points to regions in the 
interface that feature the differences between the two systems being compared. 
5.2.1. CP-DNA forms more interface contacts compared to OX-DNA 
We first analyzed the distribution of total number of interface contacts formed by 
CP- and OX-DNA in complex with HMGB1a. We observed that the distribution of total 
number of interface contacts in OX-DNA fitted well to a single Gaussian distribution 
centered at 705 ± 77. CP-DNA fitted well to two Gaussian distributions centered at 
741±75 and 836±57 (Figure 5.9). Thus, the distribution of number of interface contacts 
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observed in CP-DNA is significantly right-shifted compared to OX-DNA. Furthermore, the 
second Gaussian distribution representing CP-DNA features much more contacts than 
the first distribution, which is around the same range as OX-DNA. The higher number of 
contacts in CP-DNA would indicate a stronger complex of HMGB1a with CP-DNA 
compared to OX-DNA as seen experimentally. 
To analyze this phenomenon further, we divided the CP-DNA ensemble into two 
extreme regions (shown shaded in Figure 5.9): the “high contacts” structures that form 
the right half of the second Gaussian distribution, and the “low contacts” structures that 
form the left half of the first Gaussian distribution. Utilizing only the extreme halves of the 
Gaussian distributions ensures that we do not analyze features of the interface that 
might be common to these two distributions, thereby leading to inconsistent conclusions. 
 
Figure 5.9. Distribution of the total number of interface contacts seen in HMGB1a complex 
with CP-DNA and OX-DNA 
Black dots and red squares represent the raw distribution for CP- and OX-DNA respectively. The 
solid lines are the fitted Gaussian distributions. The dashed lines represent the individual 
Gaussian distributions that are added up to fit to the distribution of CP-DNA. The shaded regions 
represent the high and low contact ensembles. 
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5.2.2 Pt-GG roll correlates with number of interface contacts 
We asked if the higher number of interface contacts in CP-DNA compared to OX-
DNA was due to increased flexibility of CP-DNA as evidenced by the roll of the Pt-GG 
base-pair step. To test this hypothesis, we divided the distribution of the Pt-GG roll into 
quartiles and constructed a distribution of the number of Protein-DNA interface contacts 
corresponding to structures in each of the quartiles of the Pt-GG roll distributions. We 
observe that for both CP- and OX-DNA, the mean number of interface contacts 
increases as we proceed from the structures in the lowest to the highest quartile of the 
Pt-GG roll. Of course, this effect is much more pronounced in CP-DNA due to the 
presence of much higher number of interface contacts when compared to OX-DNA 
(Figure 5.10).  
 
Figure 5.10. Distribution of the number of interface contacts of structures that are part of 
different quartiles of the Pt-GG roll distribution. 
The division of the Pt-GG distribution is illustrated in the left panel, with structures corresponding 
to each quartile shaded in black, red, green and blue respectively. The distribution of total 
interface contacts of the structures corresponding to each of these quartiles is plotted in the right 
panel in the respective colors. We can observe the distributions shifting to the right as we move 
from the first quartile to the fourth. 
When we look at the reverse question, i.e., does the high-contact ensemble 
feature much higher roll than the low-contact ensemble, we find that indeed the 
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difference between the Pt-GG roll of OX-DNA and high-contact ensemble is much higher 
the difference seen in comparing CP-DNA overall and OX-DNA(Figure 5.11). More 
importantly, the low-contact ensemble has a distribution of Pt-GG roll identical to OX-
DNA. Thus, one of the physical basis of higher roll leading to higher affinity would be the 
better formation of protein-DNA interface at higher roll angles of the Pt-GG base-pair 
step. 
 
Figure 5.11. The distribution of Pt-GG roll of OX-DNA and different ensembles of CP-DNA 
bound to HMGB1a. 
The Pt-GG roll of high-contact and low-contact ensemble of CP-DNA and the overall distribution 
for OX-DNA are plotted. 
5.2.3 Comparison of protein-DNA interface between CP- and OX-DNA 
The difference in number of interface contacts between CP- and OX-DNA could 
arise due to two scenarios. In the first scenario, CP-DNA could be forming some distinct 
contacts with HMGB1a that are not seen in OX-DNA complex. In the second scenario, 
same residues in HMGB1a may be forming contacts in both CP- and OX-DNA, but in 
CP-DNA, these residues may pack better against DNA, leading to a higher number of 
contacts. The two scenarios lead to different ways to control the differential binding 
affinity of HMGB1a to CP- and OX-DNA. In the first scenario, mutating the residues 
forming contacts only with CP-DNA could abrogate differential affinity. In the second 
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scenario, it is the flexibility of Pt-DNA as a whole that is contributing to a better interface 
with HMGB1a overall.  
In order to understand the origin of the difference in number of interface contacts 
between CP- and OX-DNA, we analyzed the contact map of the protein-DNA interface. 
The contact map plots out the number of atomic contact between each residue of the 
protein and each base of the DNA in the form of a matrix (the protein residues are on the 
X-axis and the DNA bases on the Y-axis). By comparing the contact map calculated 
from the crystal structure with those obtained from OX-DNA and CP high- and low-
contact ensembles, we observe that the contacts seen in the crystal structure are well 
preserved in both CP- and OX-DNA (Figure 5.12).  
 
Figure 5.12. Contact maps of the HMGB1a-Pt-DNA interface 
Each square on the contact map represents the interaction between a protein residue and a DNA 
base. The color of the square indicates the number of heavy atom contacts involving the residue 
and the base. The scale of color used is shown on right. The contact maps are plotted for the 
crystal structure (A), the overall OX-DNA ensemble (B), the high contact ensemble (C) and low 
contact ensemble (D) of CP-DNA. 
We also observe additional contacts in CP- and OX-DNA corresponding to the N-
terminal and C-terminal tails that do not adopt any secondary structure. In the crystal 
structure, these regions are static, thus forming fewer contacts compared to the MD 
ensembles, where they form much more contacts. Comparing CP- and OX-DNA reveals 
that they too form similar contacts. Thus, the observed difference in the total number of 
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interface contacts should arise from the differences in the strength of the same contacts 
formed by CP- and OX-DNA. To explore this idea further, we next plot the difference 
contact map. Here, the contact map of OX-DNA is subtracted from the maps of overall 
CP-DNA, high contact and low contact (Figure 5.13). 
 
Figure 5.13. Difference Contact maps of the HMGB1a-Pt-DNA interface 
The difference contact map obtained by subtracting the OX-DNA contact map from the overall 
CP-DNA contact map (B), the contact map of high contact ensemble (C) and the contact map of 
the low contact ensemble (D) are shown. The contact map of the crystal structure (A) is plotted 
for reference. The scale of differences (from -10 to 30) is shown on right. 
In this difference map, blue colors would indicate more contacts formed in OX-
DNA between a residue and a base, while red and black colors would indicate stronger 
contacts formed by CP-DNA. Even when comparing overall CP- and OX-DNA, we find 
several contacts are stronger in CP-DNA compared to OX-DNA. This effect is even more 
pronounced in the high contact ensemble, while several places, especially Phe37 show 
more favorable contacts with OX-DNA when compared with the low contact ensemble. 
In order to explore if there is a specific region in the interface that shows up preferentially 
in high contact ensemble when compared with OX-DNA, we highlighted all the protein 
residues that form at least 3 more contacts on average with high contact ensemble 
compared to OX-DNA (Figure 5.14). As expected from the difference map, we observe 
residues right from the 5’side of the adduct to the end of DNA on the interface having a 
difference in number of contacts between OX-DNA and the high contact ensemble. In 
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summary, we find that CP-DNA has a higher number of interface contacts compared to 
OX-DNA mainly due to the fact that the interface as a whole forms more contacts rather 
than distinct residues in CP- and OX-DNA forming differential contacts. 
 
Figure 5.14. The HMGB1a-CP-DNA complex showing residues that formed increased 
number of contacts with CP-DNA compared to OX-DNA. 
The protein and DNA molecules are shown in cartoon representation, with the residues that form 
at least 3 contacts more in high-contact CP-DNA ensemble compared to OX-DNA are shown as 
scaled spheres. The figure was created using PyMOL (www.pymol.org) 
5.3. Conclusions 
We analyzed the free and bound Pt-DNA ensembles for structural characteristics 
that report on their ability to bind HMGB1a. Based on the structural data available for 
HMGB1a, we can summarize the main parameters that influence binding as the roll of 
the Pt-GG base-pair step, the overall bend angle, the Ser41 hydrogen bond. The 
analysis of free Pt-DNA ensembles provided insight into the discriminating factors in the 
recognition step of complex formation, while analysis of the HMGB1a-Pt-DNA 
ensembles provided insight on the final tight complex of protein and DNA. Regarding 
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Phe37 intercalation, in free Pt-DNA, we found that CP-DNA had a higher population of 
structures in the region of Pt-GG roll that was favorable for Phe37 intercalation 
compared to OX-DNA. Thus, in terms of recognition by Phe37, CP-DNA was in a more 
favorable conformation for larger amount of time compared to OX-DNA. Similarly when 
HMGB1a was bound, CP-DNA displayed higher mean Pt-GG roll, implying better 
intercalation by Phe37 compared to OX-DNA. 
With respect to the Ser41 hydrogen bond, the free Pt-DNA simulations revealed 
that clearly, OX-DNA was poised to form this interaction much better than CP-DNA. The 
conformation on the 3’ side of the minor conformations of free OX-DNA was favorable 
for the formation of the Ser41 hydrogen bond. Similarly, in the bound form, OX-DNA 
formed this hydrogen bond ~10% more compared to CP-DNA, mainly because of CP-
DNA’s preference to form the A8-N7 hydrogen bond, which placed the 3’ base in a 
conformation that was unfavorable for the formation of Ser41 hydrogen bond. 
Interestingly, we observe similar hydrogen bonds by Ser41 in all three sequence 
contexts we studied, indicating the adaptability of HMGB1a to various sequences. The 
energetic contribution of the Ser41 hydrogen bond however is much higher in AGGC 
and TGGT sequence contexts compare to the TGGA sequence context. 
Finally, the interface of HMGB1a with the minor groove of Pt-DNA plays an 
important role in determining the overall binding affinity of HMGB1a to Pt-DNA. 
Strikingly, we observe CP-DNA to form more interface contacts in the minor groove 
compared to OX-DNA. Thus, clearly CP-DNA will feature higher binding affinity to 
HMGB1a compared to OX-DNA according to our simulations, which is what is observed 
experimentally also. Unexpectedly, we found that Pt-GG roll also correlated with the 
strength of the rest of the binding interface. Higher roll was accompanied by higher 
number of interface contacts. This observation lead us to conclude that the Pt-GG roll 
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and hence the flexibility of Pt-DNA is responsible for the extent of interface formed by 
HMGB1a. Furthermore, by analyzing the interface contact map, we determined that the 
effect of forming higher number of contacts arises from contributions from all regions of 
the interface and not just few distinctive contacts. Thus, the interface analysis shows that 
higher flexibility of Pt-DNA results in an overall tighter complex with HMGB1a. 
 
Chapter 6. Conclusions and Future Directions 
6.1. Conclusions 
We started this study with the hypothesis that the differences in binding affinities 
of different proteins to CP- and OX-DNA could arise due to the differences in flexibility 
that are seldom observed in an average conformation. Our main hypothesis arose due to 
the fact that many experimental structures of CP- and OX-DNA did not yield significant 
differences, which in the face of differential binding affinities in the molecular level and 
differential efficacies at the cellular level posed an intriguing challenge. We proposed to 
use molecular dynamics simulations, which can efficiently probe the short time-scale 
dynamics of small biomolecular systems in the vicinity of their native states, to uncover 
the differences in flexibility between CP- and OX-DNA adducts. In Chapter 3, we 
described the results of the first such simulations on free Pt-DNA. We discovered not 
surprisingly, that the major conformations of CP- and OX-DNA are very similar. These 
data agreed well with the experimental structural studies, since the structural studies 
obtain the major conformation most efficiently. However, we discovered significant 
differences in regimes invisible to experimental studies. Only the latest techniques are 
able to probe the minor conformations of biomolecules experimentally (Ref. (Iwahara, et 
al., 2004) for example), and these studies have been restricted to a few model systems. 
Thus, MD simulations provide the best alternative to probe minor conformations that are 
close to native state. We found that the minor conformations of CP- and OX-DNA in the 
TGGA sequence context have distinct conformations on the 3’ side of the adduct. TGGA 
is the sequence in which HMGB1a exhibits the highest differential binding affinity 
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towards CP- and OX-DNA. Furthermore, HMGB1a binds asymmetrically to Pt-DNA, with 
most interactions on the 3’ side of the adduct. Thus, simulations of free Pt-DNA by 
themselves provided important clues towards the origin of the differential binding affinity 
through differences in flexibility, and the presence of minor conformations. The carrier 
ligand dependent differences in conformation seen in TGGA sequence context was 
analyzed more comprehensively by considering TGGT and AGGC sequence contexts in 
Chapter 4. These analyses sought to characterize all possible carrier ligand and 
sequence context dependent conformational states in a systematic manner. 
Each of the predictions from free Pt-DNA was tested using the simulations of 
HMGB1a-Pt-DNA in Chapter 5. We found that the predictions for roll of the platinated 
base-pair step and for the formation of Ser41 hydrogen bond were confirmed during the 
analysis of the protein-Pt-DNA ensemble. Interestingly, we also discovered the 
propensity of Ser41 to form hydrogen bonds with the base 3’ of Pt-GG adduct regardless 
of its identity. These hydrogen bonds demonstrate the ability of HMGB1a to form 
interactions even with the base (as opposed to DNA backbone) in a sequence 
independent manner. The importance of Pt-GG roll beyond intercalation by Phe37 was 
revealed by the positive correlation between the roll and the number of interface 
contacts. We also observed that the increased number of contacts seen in CP-DNA 
compared to OX-DNA was due to an overall increase in strength of contacts rather than 
a few distinctive contacts that were seen in CP-DNA but not in OX-DNA. This result 
combined with the correlation between roll and number of contacts strongly indicates 
that the main basis for differential binding affinity of HMGB1a to CP- and OX-DNA is due 
to the differences in flexibility of CP- and OX-DNA adducts. The difference in flexibility is 
most prominent in the TGGA and AGGC sequence contexts, but due to binding of 
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HMGB1a through the 3’ side of the adduct, this difference translates to differential 
binding affinity of HMGB1a significantly in the TGGA sequence context. 
6.2. Future Directions 
Our identified mechanism of differential binding could be applicable to a wide 
range of proteins that need not even possess an HMG-domain. Many of the proteins that 
are known to bind Pt-DNA adducts recognize distorted DNA and/or bind through the 
minor groove. In terms of both mode of recognition (distorted DNA) and mode of binding 
(minor groove), flexibility of Pt-DNA will play a major role in determining binding affinity. 
After our explicit demonstration of the effect of difference in flexibility translated into 
differences in the strength of the binding interface in HMGb1a, we can use a similar 
approach to rationalize differential binding by other proteins. One of the proteins that has 
been shown to have differential binding affinity to CP- and OX-DNA is tata binding 
protein (TBP) (Vichi, et al., 1997). TBP binds through the minor groove and has specific 
residues that intercalate DNA (Juo, et al., 1996). It will be interesting to study HMG-
domain proteins like SRY and LEF-1 because they bind DNA in a symmetric manner as 
opposed to HMGB1a that binds on the 3’ side of the adduct. Further structural studies of 
Pt-DNA binding to TBP, LEF-1 and SRY among other proteins will confirm our 
hypothesis regarding flexibility of Pt-DNA and binding affinity. 
Our studies have also highlighted how a carrier ligand could influence a Pt-drug’s 
biological effect. Our main motivation to perform this study was to answer the question: 
Given that CP- and OX-DNA form similar adducts on similar sites of DNA, what could be 
the basis of their differential efficacies. The 53 fold difference in binding affinity to 
HMGB1a itself could have profound impact on drug sensitivity by different tumors. 
Studies at the cellular level, tracking the effect of HMGB1a on sensitivity to CP and OX 
will inform us if the large difference in binding affinity of HMGB1a to CP- and OX-DNA is 
67 
responsible for the differential efficacy. Such studies have been difficult in the past 
because of the large degeneracy in HMG-domain proteins in the cell. However, current 
RNAi techniques can help in broad suppression of all HMG-domain containing genes for 
short periods to discern the effect of these proteins on cellular sensitivity to CP and OX.  
Our systematic analysis of the interface between HMGB1a and minor groove of 
Pt-DNA has shown several residues to have differential contacts with CP- and OX-DNA. 
Future studies can study the impact of mutating these residues identified in our study on 
the differential binding affinity of CP- and OX-DNA. Furthermore, we were able to 
discern through our simulations the differential strength of Ser41 hydrogen bonds in 
different sequence contexts and in CP- and OX-DNA. Thus, the Ser41Ala mutation in 
HMGB1a will have differential effects on binding affinity that is dependent upon both the 
sequence context and the carrier ligand. Hence, binding experiments with Ser41Ala 
HMGB1a will yield new insights on sequence specificity of HMGB1a with respect to Pt-
DNA. 
To conclude, our simulations of free Pt-DNA and HMGB1a-Pt-DNA helped 
explain the effect of sequence context and carrier ligand on HMGB1a binding affinity to 
Pt-DNA. Furthermore, our studies have led to several predictions that can be tested 
experimentally in the future. 
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